<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2024.1384420</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular and Infection Microbiology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Regulation of immune responses to infection through interaction between stem cell-derived exosomes and toll-like receptors mediated by microRNA cargoes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Moghaddam</surname>
<given-names>Mehrdad Moosazadeh</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/374098"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Behzadi</surname>
<given-names>Elham</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sedighian</surname>
<given-names>Hamid</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goleij</surname>
<given-names>Zoleikha</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kachuei</surname>
<given-names>Reza</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Heiat</surname>
<given-names>Mohammad</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/995501"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fooladi</surname>
<given-names>Abbas Ali Imani</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/404506"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Tissue Engineering and Regenerative Medicine Research Center, Baqiyatallah University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>The Academy of Medical Sciences of I.R. Iran</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Fei Mao, Jiangsu University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Mohammad Majidi, Food &amp; Drug Administration of Iran, Iran</p>
<p>Dekai Zhang, Texas A and M University, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Abbas Ali Imani Fooladi, <email xlink:href="mailto:imanifouladi.a@gmail.com">imanifouladi.a@gmail.com</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>14</volume>
<elocation-id>1384420</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>02</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Moghaddam, Behzadi, Sedighian, Goleij, Kachuei, Heiat and Fooladi</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Moghaddam, Behzadi, Sedighian, Goleij, Kachuei, Heiat and Fooladi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Infectious diseases are among the factors that account for a significant proportion of disease-related deaths worldwide. The primary treatment approach to combat microbial infections is the use of antibiotics. However, the widespread use of these drugs over the past two decades has led to the emergence of resistant microbial species, making the control of microbial infections a serious challenge. One of the most important solutions in the field of combating infectious diseases is the regulation of the host&#x2019;s defense system. Toll-like receptors (TLRs) play a crucial role in the first primary defense against pathogens by identifying harmful endogenous molecules released from dying cells and damaged tissues as well as invading microbial agents. Therefore, they play an important role in communicating and regulating innate and adaptive immunity. Of course, excessive activation of TLRs can lead to disruption of immune homeostasis and increase the risk of inflammatory reactions. Targeting TLR signaling pathways has emerged as a new therapeutic approach for infectious diseases based on host-directed therapy (HDT). In recent years, stem cell-derived exosomes have received significant attention as factors regulating the immune system. The regulation effects of exosomes on the immune system are based on the HDT strategy, which is due to their cargoes. In general, the mechanism of action of stem cell-derived exosomes in HDT is by regulating and modulating immunity, promoting tissue regeneration, and reducing host toxicity. One of their most important cargoes is microRNAs, which have been shown to play a significant role in regulating immunity through TLRs. This review investigates the therapeutic properties of stem cell-derived exosomes in combating infections through the interaction between exosomal microRNAs and Toll-like receptors.</p>
</abstract>
<kwd-group>
<kwd>microbial infection</kwd>
<kwd>stem cell-derived exosomes</kwd>
<kwd>toll-like receptors</kwd>
<kwd>immunomodulation</kwd>
<kwd>host-directed therapy</kwd>
</kwd-group>
<counts>
<fig-count count="5"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="217"/>
<page-count count="19"/>
<word-count count="10817"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Bacteria and Host</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>In recent years, the widespread and uncontrolled use of antibiotics has led to the spread of antibiotic-resistant strains. This resistance to conventional antibiotics has led to a significant increase in mortality from infectious diseases (<xref ref-type="bibr" rid="B118">Moravej et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B171">Tang KWK. et&#xa0;al., 2023</xref>). Some scientific reports show that infectious diseases will be the leading cause of death by 2050 (<xref ref-type="bibr" rid="B31">de Kraker et&#xa0;al., 2016</xref>). Therefore, there is a need for newer approaches to improve treatment procedures to minimize the significant morbidity and mortality associated with infectious diseases (<xref ref-type="bibr" rid="B114">Moghaddam et&#xa0;al., 2015</xref>). Recent studies on pathogen-host interactions, pathogenesis, host innate and adaptive immune responses, and inflammatory pathways have led to the identification and development of diverse and comprehensive approaches based on host-directed therapy, which have now become useful strategies for the treatment of infectious diseases (<xref ref-type="bibr" rid="B177">Varma et&#xa0;al., 2020</xref>). In general, host-directed therapy involves the use of products that alone or simultaneously can result in strengthening host defense mechanisms or reducing excessive inflammation, leading to improved clinical outcomes by reducing complications, mortality, and organ injury, and improving their long-term function (<xref ref-type="bibr" rid="B77">Kaufmann et&#xa0;al., 2018</xref>). This treatment approach includes pharmaceutical agents with good safety profiles, immunomodulatory agents, biological components such as monoclonal antibodies, cytokines and vitamins, nutritional supplements, and cell therapy or cell products (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B217">Zumla et&#xa0;al., 2016</xref>). Host-directed therapies can increase the efficiency of immune responses in three ways, which include improving the host&#x2019;s cellular responses to pathogens, targeting virulence factors that cause disease, and activating immunological memory and innate and adaptive immune responses (<xref ref-type="bibr" rid="B217">Zumla et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B181">Wallis et&#xa0;al., 2023</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Different pharmaceutical agents, which can be used in host-directed therapy (HDT). These approaches lead to complete treatment of the disease or improvement of symptoms.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-14-1384420-g001.tif"/>
</fig>
<p>The innate immune system serves as a rapid defense mechanism against invading microbes and enables the adaptive immune system to respond to pathogen-specific antigens (<xref ref-type="bibr" rid="B107">Marshall et&#xa0;al., 2018</xref>). Activation of the innate immune system for a short time is beneficial as it triggers cellular protective mechanisms for tissue repair. However, prolonged or excessive activity of immune system is harmful and can lead to irreversible changes in organ structure and function (<xref ref-type="bibr" rid="B188">Warrington et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B147">Riera Romo et&#xa0;al., 2016</xref>). Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) that play a crucial role in detecting microbial invasions and triggering innate and adaptive immune responses, making them a key component of the innate immune responses (<xref ref-type="bibr" rid="B46">Fitzgerald and Kagan, 2020</xref>; <xref ref-type="bibr" rid="B96">Li and Wu, 2021</xref>). PRRs are thought to function as germline-encoded proteins that identify conserved microbial products called pathogen-associated molecular patterns (PAMPs), thereby inducing activities that stimulate host immunity and defense (<xref ref-type="bibr" rid="B168">Suresh and Mosser, 2013</xref>). In general, activation of PRRs can be caused by PAMPs and damage-associated molecular patterns (DAMPs) trigger cellular signaling cascades through mediators such as TLRs (<xref ref-type="bibr" rid="B6">Amarante-Mendes et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B215">Zindel and Kubes, 2020</xref>). PAMP compounds are not present in the host and are also called microbe-associated molecular patterns (MAMPS). DAMPs known as alarmins, are endogenous components that are often released by stressed or injured cells. They can be classified as protein damage-associated molecular patterns, such as heat shock proteins, histones, high-mobility group box 1 protein (HMGB1), and S100 molecules, or non-protein damage-associated molecular patterns, including DNA and RNA. Recognition of alarmins is primarily mediated by the NLRP3 inflammasome, which regulates the release of IL-1&#x3b2; and IL-18 (<xref ref-type="bibr" rid="B125">N&#xfc;rnberger and Kemmerling, 2009</xref>; <xref ref-type="bibr" rid="B148">Roh and Sohn, 2018</xref>; <xref ref-type="bibr" rid="B145">Relja and Land, 2020</xref>).</p>
<p>TLR an essential component of PRRs was initially identified as a gene controlling dorsal-ventral polarity of the Drosophila embryo. However, further research revealed its role in antifungal immunity (<xref ref-type="bibr" rid="B38">El-Zayat et&#xa0;al., 2019</xref>). The discovery of these receptors has brought attention to the innate immune system. To this day, 10 human and 13 mouse subtypes of TLRs have been identified. TLRs have the ability to recognize both external PAMPs and internal DAMPs (<xref ref-type="bibr" rid="B35">Duan et&#xa0;al., 2022</xref>). These molecules are expressed and present on all cells of the innate immune system including dendritic cells (DCs), macrophage, natural killer (NK) cells, basophils, neutrophils, mast cells, eosinophil, as well as non-immune cells like mesenchymal stem cells (<xref ref-type="bibr" rid="B116">Monlish et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B83">Kim et&#xa0;al., 2023</xref>). TLR activation leads to the initiation of signaling cascades in the host, which serve as a defense mechanism against invaders and promote the release of inflammatory cytokines and immune modulators to repair damaged tissues (<xref ref-type="bibr" rid="B4">Ali Imani Fooladi et&#xa0;al., 2011</xref>). On the other hand, excessive activation of TLR disrupts immune homeostasis leading to the production of pro-inflammatory cytokines and chemokines. This ultimately contributes to the development and progression of various diseases, including sepsis, cancer, and autoimmune diseases (<xref ref-type="bibr" rid="B46">Fitzgerald and Kagan, 2020</xref>; <xref ref-type="bibr" rid="B152">Sameer and Nissar, 2021</xref>).</p>
<p>Sepsis is one of the most important bacterial infectious diseases and one of the primary factors leading to death on a global scale (<xref ref-type="bibr" rid="B57">Guarino et&#xa0;al., 2023 2023</xref>). Despite primary care management, the incidence of severe sepsis rising and mortality rate is noticeably high due to the prevalence of antibiotic resistance. Standard protocol for resuscitation of septic patients is to prescribe antibiotics and prevent organ failure. But in general, no treatment is available to target the underlying mechanism of sepsis (<xref ref-type="bibr" rid="B146">Rhee et&#xa0;al., 2020</xref>; <xref ref-type="bibr" rid="B156">Schinkel et&#xa0;al., 2020</xref>). The only medication specifically approved for sepsis is recombinant activated human protein C (rhAPC, Xigris<sup>&#xae;</sup>, Eli Lilly). However, it was recently withdrawn due to unfavorable findings from the PROWESS-SHOCK trial, which failed to demonstrate a decrease in mortality rate in patients experiencing septic shock at 28 or 90 days (<xref ref-type="bibr" rid="B15">Bernard et&#xa0;al., 2001</xref>; <xref ref-type="bibr" rid="B165">Sol&#xe0; et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B155">Savva and Roger, 2013</xref>). In general, sepsis is caused by an irregular response of the host&#x2019;s immune system to primary infection, which is characterized by tissue damage and organ failure due to inflammation and suppression of the immune system leading to secondary infection. As previously stated, the recognition of microbial structures (MAMPs) triggers the immune response to infectious agents. This recognition occurs through receptor families that are part of PRR family including nucleotide binding oligomerization domains (NODs)-like receptors (NLRs), c-type lectin receptors (CLRs, including dectin-1, dectin-2, DC-SIGN), RIG-I-like receptors (RLRs, RIG-I, and MDA5), intra-cytosolic DNA sensors, and TLRs (<xref ref-type="bibr" rid="B155">Savva and Roger, 2013</xref>; <xref ref-type="bibr" rid="B161">Shekarian et&#xa0;al., 2017</xref>). When microbial ligands binds to PRRs, mediators like cytokines are released, which help to control and start the inflammatory reactions required to get rid of pathogens and boost the adaptive immune system (<xref ref-type="bibr" rid="B214">Zheng et&#xa0;al., 2020</xref>). TLRs are important in bridging the gap between innate and adaptive immunity. They are capable to identify both invasive pathogens and endogenous threat molecules released from injured or dying cells. TLRs are one of the primary components of the immune response to infectious agents (<xref ref-type="bibr" rid="B108">Medzhitov, 2001</xref>). On the other hand, excessive TLR activation may eventually cause an immune system imbalance, raising the possibility of inflammation (<xref ref-type="bibr" rid="B38">El-Zayat et&#xa0;al., 2019</xref>). According to studies, various regulatory factors that control TLR activation can also influence the negative feedback of TLR-dependent signaling. Furthermore, TLR signaling pathway antagonists and inhibitors represent a significant therapeutic approach. Accordingly, targeting TLRs is highly significant for the treatment of chronic bacterial and viral infections. Overall, there is a great promise for the prevention and management of infectious diseases with TLR-based targeted therapies (<xref ref-type="bibr" rid="B78">Kawasaki and Kawai, 2014</xref>; <xref ref-type="bibr" rid="B8">Anwar et&#xa0;al., 2019</xref>; <xref ref-type="bibr" rid="B52">Girkin et&#xa0;al., 2022</xref>).</p>
<p>According to the studies, mesenchymal stem cells (MSCs) are TLR-containing non-immune cells. These receptors are one of the effective factors in regulating MSC function (<xref ref-type="bibr" rid="B21">Chen et&#xa0;al., 2013</xref>). MSCs are sensitive to altering inflammatory conditions. Accordingly, in sites of damage or inflammation, the exposure of stem cells to TLR ligands causes the activation of TLR-related receptors and the function of these cells is regulated to control the inflammatory response (<xref ref-type="bibr" rid="B134">Pevsner-Fischer et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B1">Abdi et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B51">Gholizadeh-Ghaleh Aziz et&#xa0;al., 2021</xref>). In recent years, stem cell-derived exosomes have received much attention as factors regulating the immune system. The significant advantage of exosomes is that they have many characteristics of their parent cells, and on the other hand, exosomes do not have many of the limitations that exist in the use of cells (<xref ref-type="bibr" rid="B117">Moosazadeh Moghaddam et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B40">Essola et&#xa0;al., 2024</xref>). Studies have proven that cell receptors such as TLRs can be transferred from cell to cell through exosomes to cause functional changes in the recipient cells. It is also possible to deliver a variety of cellular mediators that regulate the function of cells to the target cells using exosomes as valuable carriers and therefore can be exploited for therapeutic purposes (<xref ref-type="bibr" rid="B95">Li et&#xa0;al., 2022</xref>). The HDT approach underpins the therapeutic effects of exosomes on the immune system. The stem cell-derived exosomes function in HDT through immune regulation and modulation, tissue regeneration stimulation, and decreased toxicity to the host (<xref ref-type="bibr" rid="B207">Zhang et&#xa0;al., 2019</xref>; <xref ref-type="bibr" rid="B117">Moosazadeh Moghaddam et&#xa0;al., 2023</xref>). Accordingly, studies have demonstrated that one of the most significant exosomal cargoes that can control inflammatory responses is microRNA (miRNA). These cargoes target elements of TLR signaling pathways in MSCs or cells that interact with them (<xref ref-type="bibr" rid="B1">Abdi et&#xa0;al., 2018</xref>).</p>
<p>Given that TLRs are one of the mediators of interest in the HDT, this review investigates the therapeutic potential of exosomes derived from stem cells against microbial infection based on interactions between exosomes and Toll-like receptors mediated by miRNA cargoes.</p>
</sec>
<sec id="s2">
<title>Toll-like receptors</title>
<p>Among the PRR family, Toll-like receptors have received more attention and investigation because of their significant function in host defense and involvement in a number of pathological processes, such as acute lung injury (ALI), and sepsis (<xref ref-type="bibr" rid="B90">Lafferty et&#xa0;al., 2010</xref>; <xref ref-type="bibr" rid="B180">Vijay, 2018</xref>). TLRs are type I transmembrane proteins composed of three domains including I) an extracellular leucine-rich repeat (LRR) domain that mediates recognition of PAMPs, II) a trans-membrane domain, and III) a cytoplasmic Toll-interleukin 1 receptor (TIR) domain which triggers downstream signaling (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>) (<xref ref-type="bibr" rid="B38">El-Zayat et&#xa0;al., 2019</xref>; <xref ref-type="bibr" rid="B86">Kornilov et&#xa0;al., 2023</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Structure of Toll-like receptor.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-14-1384420-g002.tif"/>
</fig>
<p>There are approximately 10 functional TLRs (TLR1-10) in humans and 12 functional TLRs in mice (TLR1-9, TLR11-13; TLR10 is not present in mice). These TLRs are involved in the detection of different microbial products (<xref ref-type="bibr" rid="B76">Kang and Lee, 2011</xref>; <xref ref-type="bibr" rid="B194">Xia et&#xa0;al., 2021</xref>), the cell surface or intracellular compartments like ER, endosome, endolysosome, lysosome contain TLRs. Therefore, TLRs can be primarily categorized into two distinct subfamilies, namely cell surface TLRs and intracellular TLRs, based on their specific distribution within the cell. While intracellular TLRs are found in the endosome and include TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, and TLR13, cell surface TLRs include TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>) (<xref ref-type="bibr" rid="B19">Chang, 2010</xref>; <xref ref-type="bibr" rid="B112">Mielcarska et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B53">Giurini et&#xa0;al., 2022</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>The cellular localization of Toll-like receptors (TLRs) and a variety of PAMPs and DAMPs which can specifically stimulate different TLRs. These receptors can be categorized as follows: TLRs 1, 2, 4, 5, and 6 are present on the outer surface of cells, whereas TLRs 3, 7, 8, and 9 are found within the cell, namely on endosomal membranes. Upon binding to their specific ligands, it is believed that TLRs 3, 4, 5, 7, and 9 initiate signaling through their homodimers. However, depending on the particular ligand involved, TLR2 can form heterodimers with either TLR1 or TLR6.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-14-1384420-g003.tif"/>
</fig>
<p>While intracellular TLRs are primarily capable of identifying nucleic acids derived from bacteria and viruses as well as self-nucleic acids in disease states like autoimmunity, cell surface TLRs are primarily able to identify components of microbial membranes. Research has demonstrated that proper TLR cellular localization plays a key role in controlling signaling, and that downstream of TLRs, cell type-specific signaling determines distinct innate immune responses (<xref ref-type="bibr" rid="B130">Pandey et&#xa0;al., 2015</xref>; <xref ref-type="bibr" rid="B35">Duan et&#xa0;al., 2022</xref>).</p>
<p>Many microbial agents, including porins, lipoproteins, peptidoglycan, glycoproteins, and glycosylphosphatidylinositol (GPI) anchors from Gram-positive and -negative bacteria, mycobacteria, fungi, mycoplasma, fungi, parasites, and viruses are sensed by TLR2 heterodimers in association with either TLR1 or TLR6 (and possibly TLR10). From Gram-negative bacteria, TLR4 can detect LPS (<xref ref-type="bibr" rid="B42">Farhat et&#xa0;al., 2008</xref>; <xref ref-type="bibr" rid="B70">Irvine et&#xa0;al., 2013</xref>). After LPS detection, this TLR shuttles to the late endosome to initiate alternative signaling (<xref ref-type="bibr" rid="B127">Oliveira-Nascimento et&#xa0;al., 2012</xref>). Flagellin of bacterial flagella is detected by TLR5. In order to detect microbial nucleic acids, TLR3, TLR7, TLR8, and TLR9 are specifically expressed in endosomal compartments. While TLR7, TLR8, and TLR9 recognize unmethylated CpG motif-containing DNA, TLR3 is responsible for identifying viral double-stranded RNA (dsRNA), small interfering RNAs, and self-RNAs generated from damaged cells (<xref ref-type="bibr" rid="B155">Savva and Roger, 2013</xref>; <xref ref-type="bibr" rid="B152">Sameer and Nissar, 2021</xref>; <xref ref-type="bibr" rid="B84">Kircheis and Planz, 2023</xref>). The identification of TLR10 as a sensor for the HIV-1 gp41 protein has been a recent development; however, its precise biological roles in humans remain incompletely understood (<xref ref-type="bibr" rid="B48">Fore et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B84">Kircheis and Planz, 2023</xref>). TLR11 is localized in the endolysosome and recognizes flagellin, a profilin-like molecule derived from <italic>Toxoplasma gondii</italic>, and an unidentified proteinaceous component of uropathogenic <italic>Escherichia coli</italic> (UPEC) (<xref ref-type="bibr" rid="B143">Qiu et&#xa0;al., 2023</xref>). Similar to TLR11, which recognizes profilin from <italic>T. gondii</italic>, TLR12 is primarily expressed in myeloid cells. TLR12 and TLR11 function as a homodimer or a heterodimer (<xref ref-type="bibr" rid="B167">Stejskalova et&#xa0;al., 2023</xref>). Also, TLR13 recognizes bacterial 23S rRNA (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>, <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B92">Li and Chen, 2012</xref>; <xref ref-type="bibr" rid="B54">Goulopoulou et&#xa0;al., 2016</xref>). TLR1, TLR2, and TLR4-6 have been primarily been involved in host response to bacterial and fungal infection, so it is not surprising that endosomal TLRs have been primarily assisted in host defenses against viruses (<xref ref-type="bibr" rid="B155">Savva and Roger, 2013</xref>; <xref ref-type="bibr" rid="B46">Fitzgerald and Kagan, 2020</xref>). Accordingly, endosomal TLRs are mainly involved in the defense against viruses, while TLR1, TLR2, and TLR4-6 are primarily engaged in the host response to infections caused by bacteria and fungi (<xref ref-type="bibr" rid="B155">Savva and Roger, 2013</xref>; <xref ref-type="bibr" rid="B54">Goulopoulou et&#xa0;al., 2016</xref>). It should be noted that under normal conditions, endosomal TLRs do not respond to endogenous RNAs. It has been demonstrated that self-RNAs carry a number of naturally occurring 2&#x2032; modifications including 2&#x2032;<italic>O</italic>-methyl and pseudouridine modifications, which abrogate TLR-7 and TLR-8 signaling. Additionally, it was also shown that immune stimulation was suppressed by 2&#x2032;<italic>O</italic>-methyl, 2&#x2032;-deoxy, and 2&#x2032;-fluoro substitutions on the ribose backbone of synthetic RNAs suggesting that RNA modifications play a crucial role in the immune escape (<xref ref-type="bibr" rid="B113">Mobergslien and Sioud, 2014</xref>; <xref ref-type="bibr" rid="B49">Freund et&#xa0;al., 2019</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Toll-like receptors, their ligands and origin of ligands (<xref ref-type="bibr" rid="B155">Savva and Roger, 2013</xref>).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Toll-like receptor</th>
<th valign="middle" align="center">Cellular localization</th>
<th valign="middle" align="center">Adaptor molecule</th>
<th valign="middle" align="center">Ligand</th>
<th valign="middle" align="center">Source</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">TLR1 (with TLR2)</td>
<td valign="middle" align="center">Cell Surface</td>
<td valign="middle" align="center">MyD88/TIRAP</td>
<td valign="middle" align="center">Triacyl Lipopeptides<break/>Soluble Factors</td>
<td valign="middle" align="center">Bacteria &amp; Mycobacteria<break/>
<italic>Neisseria meningitidis</italic>
</td>
</tr>
<tr>
<td valign="middle" align="center">TLR2 (with TLR1 or TLR6)</td>
<td valign="middle" align="center">Cell Surface</td>
<td valign="middle" align="center">MyD88/TIRAP</td>
<td valign="top" align="center">Lipoproteins &amp; Lipopeptides<break/>Lipoteichoic Acid<break/>Lipoarabinomannan<break/>Peptidoglycan<break/>Atypical LPS<break/>Phenol-soluble Modulin &amp; Porins<break/>Glycoinositolphospholipids &amp; Glycolipids<break/>Core and NS3 Proteins, dUTPase &amp; Glycoproteins<break/>Beta-glucan &amp; Mannan<break/>HSP70</td>
<td valign="middle" align="center">Various pathogens<break/>Gram-positive Bacteria<break/>Mycobacteria<break/>Bacteria<break/>
<italic>Leptospira interrogans</italic> &amp; <italic>Porphyromonas gingivalis</italic>
<break/>
<italic>Staphylococcus epidermidis</italic> &amp;<break/>
<italic>Neisseria</italic>
<break/>
<italic>Trypanosoma</italic>, <italic>Toxoplasma</italic> &amp;<break/>
<italic>Plasmodium</italic>
<break/>Hepatitis virus, Epstein&#x2013;Barr Virus &amp; Cytomegalovirus<break/>Fungi<break/>Host</td>
</tr>
<tr>
<td valign="middle" align="center">TLR3</td>
<td valign="middle" align="center">Endosomal</td>
<td valign="middle" align="center">TRIF</td>
<td valign="middle" align="center">Double-stranded RNA</td>
<td valign="middle" align="center">Viruses</td>
</tr>
<tr>
<td valign="middle" align="center">TLR4</td>
<td valign="middle" align="center">Cell Surface &amp; Endosomal</td>
<td valign="middle" align="center">MyD88/TIRAP<break/>TRIF/TRAM</td>
<td valign="middle" align="center">LPS<break/>O-linked Mannan<break/>Fusion &amp; Envelope Protein<break/>Taxol<break/>HSP60<break/>HSP70, Fibronectin &amp; Fibrinogen</td>
<td valign="middle" align="center">Gram-negative Bacteria<break/>Fungi<break/>Respiratory Syncytial Virus, Mouse Mammary Tumor Virus<break/>Plant<break/>
<italic>Chlamydia pneumoniae</italic>
<break/>Host</td>
</tr>
<tr>
<td valign="middle" align="center">TLR5</td>
<td valign="middle" align="center">Cell Surface</td>
<td valign="middle" align="center">MyD88</td>
<td valign="middle" align="center">Flagellin</td>
<td valign="middle" align="center">Flagellated Bacteria</td>
</tr>
<tr>
<td valign="middle" align="center">TLR6 (with TLR2)</td>
<td valign="middle" align="center">Cell Surface</td>
<td valign="middle" align="center">MyD88/TIRAP</td>
<td valign="middle" align="center">Diacyl Lipopeptides,<break/>Lipoteichoic Acid &amp; B-glucan</td>
<td valign="middle" align="center">
<italic>Mycoplasma</italic>, Gram-positive<break/>Bacteria, Fungi</td>
</tr>
<tr>
<td valign="middle" align="center">TLR7</td>
<td valign="middle" align="center">Endosomal</td>
<td valign="middle" align="center">MyD88</td>
<td valign="middle" align="center">Single-stranded RNA<break/>Imidazoquinoline, Loxoribine &amp;<break/>Bropirimine</td>
<td valign="middle" align="center">Viruses &amp; Bacteria<break/>Synthetic Compounds</td>
</tr>
<tr>
<td valign="middle" align="center">TLR8</td>
<td valign="middle" align="center">Endosomal</td>
<td valign="middle" align="center">MyD88</td>
<td valign="middle" align="center">Single-stranded RNA<break/>Imidazoquinoline</td>
<td valign="middle" align="center">Viruses &amp; Bacteria<break/>Synthetic Compounds</td>
</tr>
<tr>
<td valign="middle" align="center">TLR9</td>
<td valign="middle" align="center">Endosomal</td>
<td valign="middle" align="center">MyD88</td>
<td valign="middle" align="center">CpG-containing DNA<break/>Homozoin</td>
<td valign="middle" align="center">Bacteria, Viruses, Fungi<break/>
<italic>Plasmodium falciparum</italic>
</td>
</tr>
<tr>
<td valign="middle" align="center">TLR10</td>
<td valign="middle" align="center">Cell surface</td>
<td valign="middle" align="center">MyD88</td>
<td valign="middle" align="center">Lipopeptides (prediction)</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">TLR11</td>
<td valign="middle" align="center">Endosomal</td>
<td valign="middle" align="center">MyD88</td>
<td valign="middle" align="center">Flagellin</td>
<td valign="middle" align="center">Flagellated Bacteria</td>
</tr>
<tr>
<td valign="middle" align="center">TLR12</td>
<td valign="middle" align="center">Endosomal</td>
<td valign="middle" align="center">MyD88</td>
<td valign="middle" align="center">Profilin</td>
<td valign="middle" align="center">Apicomplexan Parasites</td>
</tr>
<tr>
<td valign="middle" align="center">TLR13</td>
<td valign="middle" align="center">Endosomal</td>
<td valign="middle" align="center">MyD88</td>
<td valign="middle" align="center">23S RNA</td>
<td valign="middle" align="center">Bacteria</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The horseshoe-like structure LRR and TLRs interact with their respective PAMPs or DAMPs as a homo- or heterodimer in addition to an accessory or co-receptor molecule to initiate TLR-mediated immune responses (<xref ref-type="bibr" rid="B78">Kawasaki and Kawai, 2014</xref>; <xref ref-type="bibr" rid="B18">Bz&#xf3;wka et&#xa0;al., 2023</xref>). The activation of signal transduction pathways linked to the activation of NF-kB, IRFs, or MAP kinases is initiated by TLRs upon recognition of PAMPs and DAMPs through the use of TIR domain-containing adaptor proteins such as myeloid differentiation primary response gene (MyD88), TIR domain-containing adaptor inducing interferon (IFN)&#x3b2; (TRIF), and TRIF related adaptor molecule (TRAM) (<xref ref-type="bibr" rid="B30">Deguine and Barton, 2014</xref>; <xref ref-type="bibr" rid="B2">Ahmed et&#xa0;al., 2021</xref>). The host is ultimately protected from microbial infections by this process, which also controls the expression of chemokines, pro-inflammatory cytokines, antimicrobial molecules and type I IFNs (<xref ref-type="bibr" rid="B30">Deguine and Barton, 2014</xref>; <xref ref-type="bibr" rid="B150">Saikh, 2021</xref>). TLRs also work with other molecules to identify ligands that are specific to microbes. For instance, TLR2 needs dectin-1, CD36, and CD14 in order to recognize lipopeptides and peptidoglycan, respectively (<xref ref-type="bibr" rid="B13">Behzadi et&#xa0;al., 2021</xref>). When it come to recognizing LPS, CD14 is a glycophosphatidylinositol-anchored protein collaborates with TLR4 as a co-receptor (<xref ref-type="bibr" rid="B87">Kumar, 2019</xref>). Internalization of TLRs into endosomes is facilitated by ITAM-mediated Syk- and PLC&#x3b3;2-dependent endocytosis which activates TRIF-dependent signaling. To induce proinflammatory cytokines by TLR7 and TLR9, CD14 is also needed (<xref ref-type="bibr" rid="B12">Baumann et&#xa0;al., 2010</xref>; <xref ref-type="bibr" rid="B202">Zanoni et&#xa0;al., 2011</xref>). A member of class B scavenger receptor family, CD36 functions as a co-receptor for amyloid-&#x3b2; peptide and oxidized low-density lipoprotein (LDL) (<xref ref-type="bibr" rid="B43">Febbraio and Silverstein, 2007</xref>). When a ligand is recognized, Src kinases is activated, resulting in the assembly of TLR4/TLR6 heterodimers. This in turn, causes sterile inflammation which is usually linked to DAMPs. Inflammatory cytokines, ROS and NLRP3 inflammasome activation are also induced (<xref ref-type="bibr" rid="B33">Di Gioia and Zanoni, 2015</xref>; <xref ref-type="bibr" rid="B55">Grebe et&#xa0;al., 2018</xref>).</p>
<p>Notably, MyD88 also affects other cytokine signaling pathways like IL-1 and IL-18 (<xref ref-type="bibr" rid="B85">Klekotka et&#xa0;al., 2010</xref>). TLR3 and TLR4 have the ability to elicit IFN/-reactions by recruiting TRIF. MyD88 is necessary for the synthesis of inflammatory cytokines that promote Th1 responses, whereas, the TRAM/TRIF adapter is generally known to be important for type I interferon production and dendritic cells maturation (<xref ref-type="bibr" rid="B140">Pulendran, 2005</xref>; <xref ref-type="bibr" rid="B103">Lundberg et&#xa0;al., 2013</xref>).</p>
</sec>
<sec id="s3">
<title>TLRs, immunity, and infection</title>
<p>The primary role of TLRs is their broad spectrum pathogen recognition capability. TLRs are present in every immune system cell and these receptors have specific roles in the recognition of PAMP/DAMP by immune responses. The activity of TLRs in innate immunity relies on the production of inflammatory cytokines and the induction of antimicrobial activity (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>) (<xref ref-type="bibr" rid="B3">Akira and Hemmi, 2003</xref>; <xref ref-type="bibr" rid="B136">Piccinini and Midwood, 2010</xref>; <xref ref-type="bibr" rid="B60">Hoffman et&#xa0;al., 2023</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Immune cells and their specific TLR groups, which lead to specific responses of these cells to PAMP/DAMP (<xref ref-type="bibr" rid="B60">Hoffman et&#xa0;al., 2023</xref>).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center"/>
<th valign="middle" colspan="6" align="center">Toll-like receptors</th>
</tr>
</thead>
<tbody>
<tr>
<th valign="middle" align="center"/>
<th valign="middle" align="center" style="background-color:#d9d9d9">TLR2</th>
<th valign="middle" align="center" style="background-color:#d9d9d9">TLR4</th>
<th valign="middle" align="center" style="background-color:#d9d9d9">TLR5</th>
<th valign="middle" align="center" style="background-color:#d9d9d9">TLR3</th>
<th valign="middle" align="center" style="background-color:#d9d9d9">TLR7/8</th>
<th valign="middle" align="center" style="background-color:#d9d9d9">TLR9</th>
</tr>
<tr>
<td valign="middle" align="center">
<bold>Cell type</bold>
</td>
<td valign="middle" align="center">B Cell<break/>T Cell<break/>Macrophage<break/>Dendritic Cell (DC)<break/>Monocyte<break/>Microglial</td>
<td valign="middle" align="center">B Cell<break/>Macrophage<break/>Monocyte<break/>DC<break/>Neutrophil<break/>Mast Cell</td>
<td valign="middle" align="center">T Cell<break/>Macrophage<break/>Monocyte</td>
<td valign="middle" align="center">T Cell<break/>Macrophage<break/>DC<break/>Microglial<break/>NK Cell</td>
<td valign="middle" align="center">B Cell<break/>Macrophage<break/>Monocyte<break/>Plasmacytoid DC<break/>Myeloid DC</td>
<td valign="middle" align="center">B Cell<break/>Macrophage<break/>Monocyte<break/>Plasmacytoid DC</td>
</tr>
<tr>
<td valign="middle" align="center">
<bold>Downstream effects</bold>
</td>
<td valign="middle" align="center">-Inflammatory cytokines such as TNF&#x3b1;, IL-1&#x3b2;, IL-6, IL-10, IL-12</td>
<td valign="middle" align="center">-Inflammatory cytokines such as TNF&#x3b1;, IL-1&#x3b2;, IL-6, IL-10, IL-12<break/>-TypeI IFN</td>
<td valign="middle" align="center">-Inflammatory cytokines such as IL-6, G-CSF<break/>-Chemotactic effects<break/>-T Cell stimulation</td>
<td valign="middle" align="center">-Inflammatory cytokines such as IL-6<break/>-TypeI IFN<break/>-Chemotactic effects<break/>-T Cell stimulation</td>
<td valign="middle" align="center">-Inflammatory cytokines such as IL-12<break/>-TypeI IFN</td>
<td valign="middle" align="center">-Inflammatory cytokines such as IL-1&#x3b2;, IL-6, IL-10, IL-12<break/>-TypeI IFN</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>When PAMPs or DAMPs activate TLRs, these receptors employ adapter proteins as a platform to recruit TNF receptor-associated factor 6 (TRAF6), GF-beta activated kinase 1/MAP3K7 binding protein 2 (TAB2) and IL-1R-associated protein kinases (IRAK) 1, 2, 4 (<xref ref-type="bibr" rid="B129">Pandey and Agrawal, 2006</xref>). As a result of this activity, pro-inflammatory transcription factors, activator protein 1 (AP-1), NF-kB, and interferon regulatory factor 3 (IRF3) translocate (<xref ref-type="bibr" rid="B129">Pandey and Agrawal, 2006</xref>; <xref ref-type="bibr" rid="B155">Savva and Roger, 2013</xref>). Every transcription factor engages in the transcription of distinct genes that encode various sets of proteins including chemokines (CXCL8 and CXCL10), type 1 interferon (IFN-&#x3b1;, &#x3b2;), antimicrobial peptides, and pro-inflammatory cytokines like tumor necrosis factor alpha (TNF-&#x3b1;), IL-1&#x3b2;, and IL-6 (<xref ref-type="bibr" rid="B50">Gerold et&#xa0;al., 2007</xref>).</p>
<p>Human clinical trials and animal models experiments confirm the essential function of TLRs in regulation of infectious diseases (<xref ref-type="bibr" rid="B205">Zhang et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B89">Kumar and Barrett, 2022</xref>). The primary evidence obtained from the studies that were performed using TLR4 defective C3H/HeJ and C57BL/10ScCr mice. These mice exhibited reduced responsiveness to LPS and were prone to infection of <italic>Salmonella typhimurium</italic> and <italic>Escherichia coli</italic>, which would typically not be lethal (<xref ref-type="bibr" rid="B91">Lee et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B58">Hajjar et&#xa0;al., 2012</xref>). The importance of TLR signaling in host defense has been highlighted by further studies in mice having knockout TLRs or TLR adapter molecules. Notably, mice lacking TLR2 exhibit high vulnerability to infections caused by <italic>Streptococcus pneumoniae</italic> and <italic>Staphylococcus aureus</italic> (<xref ref-type="bibr" rid="B170">Takeuchi et&#xa0;al., 2000</xref>; <xref ref-type="bibr" rid="B37">Echchannaoui et&#xa0;al., 2002</xref>). Also, there have been clinical investigations that have linked polymorphisms affecting TLR expression or TLR structure with an increased susceptibility to infection (<xref ref-type="bibr" rid="B119">Mukherjee et&#xa0;al., 2019</xref>).</p>
<p>As mentioned, one of the main features of TLRs activation in response to PAMP/DAMP is the control of the secretion of pro-inflammatory cytokines and interferons especially interferons type1 during immune responses (<xref ref-type="bibr" rid="B38">El-Zayat et&#xa0;al., 2019</xref>). Cytokines are short-lived and long-range mediators that regulate systemic responses by influencing different tissues (<xref ref-type="bibr" rid="B72">Jaffer et&#xa0;al., 2010</xref>). Although TLRs play an important role in host defense against infections through these mediators, TNF-&#x3b1; and IL-1&#x3b2; which are classified as pro-inflammatory cytokines can produce different outcomes in the host, so that in some cases by hyperactivating (cytokine storm), they disrupt the immune system and lead to an exacerbation of systemic damage caused by infection, such as in sepsis and COVID19 (<xref ref-type="bibr" rid="B26">Chousterman et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B65">Hu et&#xa0;al., 2021</xref>). Cytokine storm, which is a severe elevation in interferons, cytokines and chemokines causes intense inflammation and tissue injury and plays an important role in infectious diseases such as influenza, COVID-19 and sepsis,. The phrase &#x201c;cytokine storm&#x201d; was initially employed in 1993 in an published work discussing graft-versus-host disease (GVHD). However, it gained widespread recognition in the field of infectious diseases in 2005, primarily due to its application in H5N1 influenza infection (<xref ref-type="bibr" rid="B27">Clark, 2007</xref>).</p>
<p>Each TLR (TLR4, TLR2, TLR5, TLR9) specifically recognizes bacterial PAMPs including peptidoglycan (PGN), lipoteichoic acid (LTA), lipopolysaccharide (LPS), flagellin, purines, and CpG-DNA. These events activate the nuclear factor &#x3ba;-light-chain-enhancer of activated B cell (NF-&#x3ba;B) which in turn triggers the expression of genes responsible for the synthesis and release of inflammatory mediators (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>) (<xref ref-type="bibr" rid="B204">Zhang and Ghosh, 2001</xref>; <xref ref-type="bibr" rid="B32">Dias et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B84">Kircheis and Planz, 2023</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Intraction between PAMPs ligands and TLRs and regulating the expression of proinflammatory cytokines in the nucleus. NF-&#x3ba;B is activated by all TLRs to elevate the expression of proinflammatory cytokines in the nucleus. Furthermore, activation of interferon regulatory factor 3 (IRF3) by some TLRs such as TLR4 leads to upregulation of type 1 INF expression.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-14-1384420-g004.tif"/>
</fig>
<p>In this regard, during cytokine storm, the physical interaction between TLR5 and TLR4 directs the signaling pathway towards MyD88-dependent pathway by forming Myddosome (a complex of MyD88 and IRAK4), which activates NF-&#x3ba;B and the expression of associated downstream pro-inflammatory genes (<xref ref-type="bibr" rid="B88">Kumar, 2020</xref>; <xref ref-type="bibr" rid="B172">Tang X. et&#xa0;al., 2023</xref>). In general, the activation of TLR signaling in response to DAMPs and PAMPs relies on the signaling pathways mediated by MyD88 and TRIF. This activation subsequently triggers the activation of NF-&#x3ba;B leading to the expression and release of various pro-inflammatory cytokines and other molecules including IL-1&#x3b1;, IL-6, IL-8, TNF-&#x3b1;, reactive oxygen species (ROS), and reactive nitrogen species (RNS) (<xref ref-type="bibr" rid="B199">Yamamoto et&#xa0;al., 2003</xref>). Nevertheless, prolonged activation of TLR signaling can give rise to an excessive inflammatory response, potentially causing fetal consequences or triggering autoimmunity which is responsible for the emergence of cytokine storm, systemic inflammation and the progression of disease such as COVID19 and sepsis (<xref ref-type="bibr" rid="B128">Ospelt and Gay, 2010</xref>; <xref ref-type="bibr" rid="B105">Manik and Singh, 2022</xref>).</p>
<p>On the other hand, a variety of molecules negatively regulate TLR signaling via various mechanisms in order to stop or prevent overactivation of immune system that result in harmful outcomes linked to inflammatory and autoimmune diseases (<xref ref-type="bibr" rid="B183">Wang et&#xa0;al., 2009</xref>). Accordingly, suppressor of cytokine signaling (SOCS1; a negative regulator of Janus kinases that functions as a feedback inhibitor of cytokine signaling), peptide-mimetic MyD88 homodimerization inhibitor ST2825, and Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b; an E3 ubiquitin-protein ligase that promotes proteosome-mediated protein degradation) all inhibit the activation of MyD88-dependent pathway (<xref ref-type="bibr" rid="B78">Kawasaki and Kawai, 2014</xref>; <xref ref-type="bibr" rid="B193">Wicherska-Paw&#x142;owska et&#xa0;al., 2021</xref>), and TRAM adaptor with GOLD domain (TAG; a splice variant of the adaptor TRAM, which negatively regulates the adaptor MyD88-independent TLR4 pathway) and selective androgen receptor modulators (SARM) both inhibit the activation of the TRIF-dependent pathway (<xref ref-type="bibr" rid="B176">Ullah et&#xa0;al., 2016</xref>). In order to stop these molecules from attaching to downstream molecules or TLRs, they associate with MyD88 or TRIF (<xref ref-type="bibr" rid="B78">Kawasaki and Kawai, 2014</xref>).</p>
<p>The role of TRLs in infectious diseases and their function in regulating innate immune responses, in recent years, have drawn the attention of researchers to develop TLR-based drugs to control infections by managing TRLs signaling pathways (<xref ref-type="bibr" rid="B50">Gerold et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B35">Duan et&#xa0;al., 2022</xref>). As previously mentioned, targeting TLR signaling pathways could be beneficial as a new therapeutic method for infectious diseases control based on host-directed therapy (HDT) (<xref ref-type="bibr" rid="B81">Khan et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B77">Kaufmann et&#xa0;al., 2018</xref>). In recent years, stem cell-derived exosomes therapy have received much attention as factors regulating the immune system. The therapeutic effects of exosomes on the immune system is based on the HDT strategy (<xref ref-type="bibr" rid="B117">Moosazadeh Moghaddam et&#xa0;al., 2023</xref>).</p>
</sec>
<sec id="s4">
<title>Exosomes-TLRs intraction and infection control</title>
<p>While cytokines and chemokines are known as mediators of cellular communication to generate and regulate immune responses, recently more complex messengers such as exosomes have been considered (<xref ref-type="bibr" rid="B71">Isola A and Chen, 2017</xref>). Exosomes are the smallest extracellular vesicle (EV) structures that can be produced by a wide variety of cells. EVs are generally categorized into three main groups based on size: large-sized apoptotic bodies (1000&#x2013;5000 nm) are generated during apoptosis; medium-sized micro vesicles (100&#x2013;1000 nm) secreted from the cell plasma membrane, small-sized vesicles or exosomes (&lt;30&#x2013;150 nm) produced via the endocytic pathway (<xref ref-type="bibr" rid="B132">Pegtel and Gould, 2019</xref>; <xref ref-type="bibr" rid="B117">Moosazadeh Moghaddam et&#xa0;al., 2023</xref>). Exosomes vesicles are enclosed in a phospholipid bilayer membrane which originated from the endocytic route and the plasma membrane inward budding results in the formation of these nanovesicles (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>) (<xref ref-type="bibr" rid="B75">Kalluri and LeBleu, 2020</xref>; <xref ref-type="bibr" rid="B36">Dudzik et&#xa0;al., 2021</xref>). These components are essential for intercellular communication because they are present in nearly all body fluids. The components that exosomes carry -i.e. lipids, proteins, metabolites like mRNA, tRNA, microRNA as well as small transcripts of RNA and RNA-protein complexes, chromosomal and mitochondrial DNA-are what give them their significance (<xref ref-type="bibr" rid="B75">Kalluri and LeBleu, 2020</xref>). Studies have shown that the elements present in the exosome can be different depending on the type of cells and their physiological conditions. However, some proteins are thought to be particular exosome markers. In this context the tetraspanin family of transmembrane proteins are well-known which includes major histocompatibility complexes (MHC), heat shock proteins (HSP70 and HSP90), and GTPases and CD9, CD81 and CD63 and are among most significant conserved proteins (<xref ref-type="bibr" rid="B75">Kalluri and LeBleu, 2020</xref>; <xref ref-type="bibr" rid="B200">Yao et&#xa0;al., 2023</xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>EVs can be classified into three primary subpopulations based on the size and biogenesis process,: (i) exosomes, (ii) microvesicles (MVs), and (iii) apoptotic bodies (AB). Exosomes are produced when endosomes internally budder, resulting in multivesicular bodies (MVBs) which are then released into the extracellular space following fusion with the plasma membrane. Direct outward plasma membrane budding produces MVs. The AB is membrane blebs produced during cell apoptosis.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-14-1384420-g005.tif"/>
</fig>
<p>Exosomes have significant roles in physiology and immunity and have known to play dual roles in both immune system activation and immune suppression (<xref ref-type="bibr" rid="B117">Moosazadeh Moghaddam et&#xa0;al., 2023</xref>). However, there are evidences that exosomes generally downregulate immune processes in the absence of stress and pathology (<xref ref-type="bibr" rid="B47">Fleshner and Crane, 2017</xref>). Although they are produced by most cells, the exosomes of interest in medicine are stem cell-derived exosomes (stem cell-Exo) due to their immunological features, anti-inflammatory function, regeneration capacity, and antimicrobial function. The benefits of stem cell-Exo also include its low immunogenicity, high stability, small size, lack of tumor genesis, and easier storage needs (<xref ref-type="bibr" rid="B109">Mendt et&#xa0;al., 2019</xref>; <xref ref-type="bibr" rid="B123">Nikfarjam et&#xa0;al., 2020</xref>). As mentioned, TLRs can be transferred from the stem cells to exosome. Certainly, the presence of these receptors in the exosome is different depending on the type of stem cell from which the exosome originates (<xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>) (<xref ref-type="bibr" rid="B163">Shirjang et&#xa0;al., 2017</xref>).</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>RNA and protein levels of Toll-like receptors in different MSC sources in humans (<xref ref-type="bibr" rid="B163">Shirjang et&#xa0;al., 2017</xref>).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="center">Source of MSCs</th>
<th valign="middle" colspan="4" align="center">Gene Expression</th>
<th valign="middle" rowspan="2" align="center">Protein Expression</th>
</tr>
<tr>
<th valign="middle" align="center">High</th>
<th valign="middle" align="center">Low</th>
<th valign="middle" align="center">Not significant</th>
<th valign="middle" align="center">Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">Bone Marrow</td>
<td valign="middle" align="center">TLR2, TLR3, TLR4, TLR7, TLR8, TLR9</td>
<td valign="middle" align="center">TLR1, TLR5, TLR6, TLR10</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR9</td>
</tr>
<tr>
<td valign="middle" align="center">Adipose</td>
<td valign="middle" align="center">TLR2, TLR3, TLR4, TLR7, TLR9</td>
<td valign="middle" align="center">TLR1, TLR5, TLR6, TLR10</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">TLR8</td>
<td valign="middle" align="center">TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR9</td>
</tr>
<tr>
<td valign="middle" align="center">Umbilical Cord</td>
<td valign="middle" align="center">TLR4, TLR6</td>
<td valign="middle" align="center">TLR1, TLR3, TLR5, TLR9</td>
<td valign="middle" align="center">TLR7, TLR8, TLR10</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">TLR5, TLR4 with very low expression</td>
</tr>
<tr>
<td valign="middle" align="center">Whartons&#x2019; Jellay</td>
<td valign="middle" colspan="3" align="center">TLR1, TLR2, TLR3, TLR4, TLR5, TLR6</td>
<td valign="middle" align="center">TLR4</td>
<td valign="middle" align="center">TLR3 under inflammatory conditions</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Numerous studies have shown the ability of exosomes derived from MSCs to diminish the advancement and growth of inflammation. This is achieved through the regulation of macrophage polarization by targeting either intracellular signaling pathways or cellular metabolic pathways (<xref ref-type="bibr" rid="B9">Arabpour et&#xa0;al., 2021</xref>). MSC-Exos have a specific function where they target the PRRs&#x2019; downstream pathway which includes the NF-&#x3ba;B signaling. For instance, in order to induce M2 macrophage polarization, MSC-derived exosomes downregulate the expression of nuclear factor kappa B subunit 1. This was demonstrated by overexpression of M2 markers including arginase-1 (Arg1), IL-10, and decreased levels of M1 marker such as inducible nitric oxide synthase. Based on findings, this activity is related to the microRNAs, especially miR-27a-3p (<xref ref-type="bibr" rid="B187">Wang et&#xa0;al., 2020</xref>).</p>
<p>MicroRNAs have obtained considerable interest among exosome biomolecules because of their vital role in regulating gene expression and cellular behavior in diverse physiological and pathological conditions (<xref ref-type="bibr" rid="B206">Zhang et&#xa0;al., 2015</xref>). Based on studies, the most prevalent cargo molecules in the exosome are miRNAs, which also play a more useful functional role compared to other cargoes (<xref ref-type="bibr" rid="B64">Hu et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B206">Zhang et&#xa0;al., 2015</xref>). Numerous studies have demonstrated that the transcriptional responses of TLRs can be regulated by epigenetic processes like DNA methylation, histone modifications and the action of non-coding RNAs like miRNAs, of which miRNAs are of particular importance (<xref ref-type="bibr" rid="B16">Boosani and Agrawal, 2016</xref>; <xref ref-type="bibr" rid="B137">Poli et&#xa0;al., 2020</xref>). It has been proven that specific miRNA expressions that are upregulated in MSCs give exosomes characteristics like pro-angiogenesis, immunomodulation and anti-apoptosis (<xref ref-type="bibr" rid="B24">Cheng et&#xa0;al., 2020</xref>).</p>
<p>In a general description, through targeting of the imperfect antisense complementary regions of both coding and non-coding transcripts, miRNAs are essential elements of posttranscriptional regulation. Recent research has shown that miRNAs regulate gene expression to influence nearly every known cellular processes, including innate and adaptive immune responses (<xref ref-type="bibr" rid="B122">Nejad et&#xa0;al., 2018</xref>). The majority of miRNA genes are transcribed by RNA polymerase II, which results in the production of primary transcripts or pri-miRNAs, which are then converted into mature approximately 22-nt miRNA duplexes by RNase III DROSHA and DICER1. Investigations have revealed that the majority of single-stranded miRNAs target the 3&#x2019;-UTR region of genes; this process is governed by the RNA-induced silencing complex (RISC complex) which controls intracellular pathological processes and biological homeostasis. In other words, miRNAs affect cell behavior and fate that are essential to immune homeostasis by promoting cell activation, polarization, and the development of immunological memory cells in response to environmental stimuli and based on an epigenetic responses (<xref ref-type="bibr" rid="B126">O'Brien et&#xa0;al., 2018</xref>).</p>
<p>The majority of miRNAs are either bound to protective proteins including high-density lipoprotein and argonaute protein, or packaged into protective microvesicles like exosomes because naked miRNAs are quickly degraded in the bloodstream (<xref ref-type="bibr" rid="B213">Zhao et&#xa0;al., 2019</xref>). Studies have shown that numerous immunomodulatory miRNAs in the human blood are found in exosomes (<xref ref-type="bibr" rid="B45">Fern&#xe1;ndez-Messina et&#xa0;al., 2015</xref>). Transfer of miRNAs to exosomes occurs through an endosomal sorting complexes required for transport (ESCRT)-independent pathway. Thus, it has been demonstrated that the sorting and packaging of exosomal miRNAs in exosomes is related to a signaling pathway that is dependent on neuronal sphingomyelinase 2 (nSMase2) (<xref ref-type="bibr" rid="B124">Nik Mohamed Kamal and Shahidan, 2020</xref>; <xref ref-type="bibr" rid="B23">Chen et&#xa0;al., 2021</xref>). In addition, it has been shown that RNA-binding proteins are also involved in miRNA sorting, for example Ago2, which controls the secretion of some miRNAs in exosomes by regulating phosphorylation, or heterogeneous nuclear ribonucleoprotein (hnRNP) family proteins, which can induce miRNAs recruitment to exosome by binding to exosomal miRNAs (<xref ref-type="bibr" rid="B56">Groot and Lee, 2020</xref>).</p>
<p>As mentioned, studies have demonstrated that miRNAs can influence the signaling pathways associated with the TLRs and lead to the regulation and alteration of the immune responses such as inflammation, cellular infiltration, T-cell activation, and immunity development (<xref ref-type="bibr" rid="B59">He et&#xa0;al., 2014</xref>). As a result, miRNA has gained attention recently due to its significance in controlling TLR-dependent inflammation (<xref ref-type="bibr" rid="B115">Momen-Heravi and Bala, 2018</xref>). Investigations have shown that GU-rich miRNA sequences, can directly interact with the ribonucleic-acid binding TLR7/8 found in cellular endosomes like exosomes to activate pro-inflammatory signaling pathways in addition to their usual function of controlling gene expression through interaction with cytoplasmic RNA by direct interaction (<xref ref-type="bibr" rid="B121">Nation et&#xa0;al., 2021</xref>). So, TLRs-binding miRNA released by cells in damaged or stressed tissues, after being internalized in exosomes and secreted out, in distant recipient cells can generate inflammatory signals (<xref ref-type="bibr" rid="B1">Abdi et&#xa0;al., 2018</xref>). Several TLR7/8-binding miRNA including let-7b/c, miR-7a, miR-21, miR-29a/b, miR-34a, miR-122, miR-133a, miR-142, miR-145, miR-146a, miR-208a, and miR-210 have been shown to contribute to inflammation in sepsis, autoimmune, cancer, neurological, and graft-vs-host disease settings thus far (<xref ref-type="bibr" rid="B17">Bosch et&#xa0;al., 2020</xref>). Studies demonstrated that these miRNA directly bind to human TLR8 and mouse TLR7. The reports state that TLR7-/- knockout mice are resistant to inflammatory and degenerative effects of TLR-binding miRNA (<xref ref-type="bibr" rid="B41">Fabbri, 2012</xref>).</p>
<p>On the other hand, in a study on the role of miRNA in regulation of the immune responses, it has been proven that let-7i miRNA can regulate TLR4 expression in human cholangiocytes by directly binding to TLR4 (<xref ref-type="bibr" rid="B22">Chen et&#xa0;al., 2007</xref>). Accordingly, infection caused by <italic>Cryptosporidium parvum</italic> and LPS in cultured cholangiocytes leads to a decrease in let-7 expression through a MyD88/NFkB-dependent mechanism, and this decrease in expression is associated with upregulation of TLR4 (<xref ref-type="bibr" rid="B22">Chen et&#xa0;al., 2007</xref>). Subsequently, additional investigations revealed that the 3&#x2019; untranslated region of the cytokine-inducible Src homology 2-containing protein is the target of miR-let-7 and miR-98. This results in the translational suppression of this protein in cholangiocytes may be related to the regulation of inflammatory responses in epithelial cells during microbial infection (<xref ref-type="bibr" rid="B22">Chen et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B66">Hu et&#xa0;al., 2009</xref>). It has also been demonstrated that aberrant miR-155 expression and function are linked to the inflammation and impact immune cell function on several levels by targeting inflammation related genes, including TLRs (<xref ref-type="bibr" rid="B93">Li et&#xa0;al., 2013</xref>). The expression of the adapter protein TAB2 in the TLR/IL-1 signaling cascade is repressed by this particular miRNA, thereby playing a crucial role in regulating the feedback mechanism of IL-1&#x3b2; and other inflammatory cytokines produced during LPS-mediated DC activation (<xref ref-type="bibr" rid="B5">Alivernini et&#xa0;al., 2018</xref>). Moreover, the suppressor of cytokine signaling 1 (SOCS1) is a target of MiR-155, which can alter SOCS1 transcriptional expression in macrophages activated by LPS (<xref ref-type="bibr" rid="B141">Qayum et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B216">Zingale et&#xa0;al., 2021</xref>). In addition, miR-155 may regulate TLR3 expression in macrophages via targeting coding sequences of the TLR3 gene. These studies indicate the dual role of miRNAs in enhancing or reducing the level of immune responses due to its interactions with TLRs (<xref ref-type="bibr" rid="B1">Abdi et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B216">Zingale et&#xa0;al., 2021</xref>).</p>
<p>Cho et&#xa0;al. conducted a study that showed tonsil-derived mesenchymal stem cells (T-MSCs) and T-MSC-derived exosomes can attenuate TLR7-mediated mast cell activation in mice which leads to the reduction of skin inflammation (<xref ref-type="bibr" rid="B25">Cho et&#xa0;al., 2022</xref>). The immune system in the skin, which include mast cells, reacts to a variety of environmental and pathological stimuli, such as pathogens (<xref ref-type="bibr" rid="B74">Jim&#xe9;nez et&#xa0;al., 2021</xref>). They regulate their function through the expression of TLRs. In their study, the expression levels of inflammatory cytokines were measured after treating the human mast cell line HMC-1 with a TLR7 agonist in the presence or absence of T-MSC exosomes (<xref ref-type="bibr" rid="B25">Cho et&#xa0;al., 2022</xref>). The findings demonstrated that in HMC-1 cells treated with TLR7 agonist, the expression of inflammatory cytokines was significantly reduced by T-MSC-derived exosomes containing miRNAs that target inflammatory cytokines. Analysis revealed that in treated HMC-1 cells, the expression levels of IL-8, macrophage colony-stimulating factor (M-CSF), interferon gamma-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1 alpha (MIP-1&#x3b1;), MIP-1&#x3b2;, tumor necrosis factor alpha (TNF-&#x3b1;), and tissue inhibitor of metalloproteinases 2 (TIMP-2) were significantly upregulated in the absence of exosomes, however, these expression levels were decreased by T-MSC exosomes (<xref ref-type="bibr" rid="B25">Cho et&#xa0;al., 2022</xref>). In addition, the mRNA levels of TLR7 and Myd88, an adaptor that links TLRs to downstream molecules, were evaluated. This was done primarily by comparing the effects of treatment with exosomes derived from T-MSC- or Wharton&#x2019;s Jelly-MSCs. TLR7 and Myd88 were expressed less frequently in treated HMC-1 cells when exosomes derived from iT- or WJ-MSC were present. However, Myd88 expression was more reduced in T-MSC exosomes than in WJ-MSC exosomes (<xref ref-type="bibr" rid="B25">Cho et&#xa0;al., 2022</xref>). In addition, in mice treated with TLR7 agonist, exosomes prevented the growth of both dermal mast cells and CD14-positive cells. The outcomes demonstrated that TLR7 stimulation and mast cell activation under inflammatory conditions are regulated by exosomes derived from T-MSCs (<xref ref-type="bibr" rid="B25">Cho et&#xa0;al., 2022</xref>). Consequently, examination of miRNAs expression in T-MSCs revealed that the significant downregulation of inflammatory cytokines in treated HMC-1 cells in the presence of T-MSC exosomes may be associated with the overexpression of miR-214-3p, miR-424-5p, miR-126-5p, and miR-302c-3p (<xref ref-type="bibr" rid="B25">Cho et&#xa0;al., 2022</xref>). Apart from these findings, it is noteworthy that WJ-MSCs and their exosomes are the most attractive source of stem cells when immunosuppression is needed in inflammatory or infectious conditions (<xref ref-type="bibr" rid="B34">Drobiova et&#xa0;al., 2023</xref>). Research suggests that TLR3 and TLR4 ligation may cause a pro-inflammatory phenotype in bone marrow (BM)- and adipose (AD)-MSCs. In contrast, WJ-MSCs are resistant to TLRs ligation because they can overexpress HGF which is involved in the immune suppression that MSCs mediate, when TLR3 and TLR4 activation is present as well as because they lack expression of several TLRs (<xref ref-type="bibr" rid="B198">Yagi et&#xa0;al., 2010</xref>; <xref ref-type="bibr" rid="B151">Sallustio et&#xa0;al., 2019</xref>).</p>
<p>The pathological condition known as acute kidney injury (AKI) is characterized by the kidney&#x2019;s abrupt malfunction. Kidney failure can range from partial loss of kidney function to complete kidney failure (<xref ref-type="bibr" rid="B79">Kellum et&#xa0;al., 2021</xref>). Sepsis accounts for 20-50% of cases of AKI in critically ill patients, making it the most common cause in these patients (<xref ref-type="bibr" rid="B138">Poukkanen et&#xa0;al., 2013</xref>). Although the pathophysiology of AKI caused by sepsis is complex, however, nephrotoxins, systemic inflammation and hemodynamic changes are the most important influencing factors (<xref ref-type="bibr" rid="B20">Chang et&#xa0;al., 2022</xref>). The primary determinant of kidney inflammation severity is thought to be the release of inflammatory cytokines from damaged renal tubular cells. As a result, suppressing the inflammatory response might be essential for treating AKI (<xref ref-type="bibr" rid="B144">Ramesh and Reeves, 2004</xref>). Many studies have confirmed the potential therapeutic effects of MSCs on AKI (<xref ref-type="bibr" rid="B154">S&#xe1;vio-Silva et&#xa0;al., 2020</xref>; <xref ref-type="bibr" rid="B98">Liu Y. et&#xa0;al., 2023</xref>). For example, human umbilical cord-derived MSCs (hUC-MSCs) have been shown to be highly efficient in repairing cisplatin-induced AKI (<xref ref-type="bibr" rid="B133">Per&#x161;e and Ve&#x10d;eri&#x107;-Haler, 2022</xref>). It has additionally been demonstrated that BM-MSCs have a significant impact on improving kidney function. In this regard, Xiu et&#xa0;al. showed that BM-MSCs could alleviate the inflammation reaction in LPS-induced AKI in rats via downregulation of the level of TLR4 and NF-kB and inhibition of TLR4/NF-kB signaling pathway (<xref ref-type="bibr" rid="B195">Xiu et&#xa0;al., 2018</xref>).</p>
<p>On the other hand, in a animal study, Zang et&#xa0;al. demonstrated that exosomes derived from AD- and BM-MSCs can inhibit inflammation and oxidative stress in LPS-induced AKI (<xref ref-type="bibr" rid="B209">Zhang et&#xa0;al., 2022</xref>). However, compared to BM-MSCs exosomes, kidney function and structure were significantly improved by AD-MSCs exosomes (<xref ref-type="bibr" rid="B209">Zhang et&#xa0;al., 2022</xref>). Based on this, several research has demonstrated that miRNAs and their interactions with TLRs have a significant impact on reducing AKI (<xref ref-type="bibr" rid="B179">V&#xe1;zquez-Carballo et&#xa0;al., 2021</xref>). Liu et&#xa0;al. conducted a study that showed miRNA-342-5p in exosomes secreted from AD-MSCs via TLR9 inhibition leads to the reduction of acute kidney damage (AKI) in LPS-induced sepsis mice (<xref ref-type="bibr" rid="B99">Liu W. et&#xa0;al., 2023</xref>). This miRNA facilitates cellular autophagy by downregulating TLR9 expression, thereby leading to protection against sepsis-associated AKI. The results suggest that by influencing necrosis, inflammation, and apoptosis, selective activation of renal proximal tubule TLR9 may worsen ischemic AKI (<xref ref-type="bibr" rid="B99">Liu W. et&#xa0;al., 2023</xref>). In addition, Zhang et&#xa0;al. showed that HUC-MSCs-derived exosomes alleviate sepsis-associated AKI via regulating microRNA-146b expression (<xref ref-type="bibr" rid="B210">Zhang R. et&#xa0;al., 2020</xref>). They used HUC-MSC exosomes to study the regulatory role of exosomal miR-146b on NF-kB activity and the function of NF-kB on healing the sepsis-associated AKI. Their findings showed that the treatment with hUC-MSC-derived exosomes resulted in downregulation of interleukin (IL)-1 receptor-associated kinase (IRAK1) expression-as the target gene of miR-146b-by increasing the levels of miR-146b. This process leads to the inhibition of NF-kB activity, which ultimately improves the survival of mice with sepsis by controlling and reducing the complications of AKI related to sepsis (<xref ref-type="bibr" rid="B210">Zhang R. et&#xa0;al., 2020</xref>).</p>
<p>Another severe inflammatory and traumatic illness that can result in respiratory failure and impaired lung function is acute lung injury (ALI) with a mortality rate exceeding 30% (<xref ref-type="bibr" rid="B67">Huang et&#xa0;al., 2023</xref>). ALI can be caused by PAMP ligands such as LPS. According to recent research, autophagy provides protection against ALI (<xref ref-type="bibr" rid="B211">Zhao et&#xa0;al., 2023</xref>). Through a lysosome-dependent, regulated process, autophagy is the cell&#x2019;s natural, conserved method of eliminating unwanted or dysfunctional components. Cellular components are able to degrade and recycle in an orderly manner because of this mechanism (<xref ref-type="bibr" rid="B211">Zhao et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B44">Feng et&#xa0;al., 2024</xref>). Recently, various studies have shown that administration of hUC-MSCs can lead to reduction of ALI symptoms. Moreover, these cells exhibit a substantial enhancement in survival rates, improvement in anti-inflammatory homeostasis, and diminish in the levels of oxidative stress in LPS-induced acute lung injury (ALI) in vivo (<xref ref-type="bibr" rid="B61">Hong et&#xa0;al., 2020</xref>). In a study conducted by Wie et&#xa0;al., exosomes released from h-UC-MSCs were shown to produce autophagy in LPS-induced ALI (<xref ref-type="bibr" rid="B191">Wei et&#xa0;al., 2020</xref>). They were able to demonstrate that in LPS-induced ALI, autophagy activation offers protection. The overexpression of miR-377-3p found in hUC-MSCs exosomes is linked to this immunosuppressive effect. TLR4/NF-kB signaling inhibition and downregulation of regulatory-associated with protein of mTOR (RPTOR) significantly reduced lung injury (<xref ref-type="bibr" rid="B191">Wei et&#xa0;al., 2020</xref>). According to the studies, RPTOR inhibition prevents hypoxia-induced lung injury by increasing autophagy and decreasing apoptosis (<xref ref-type="bibr" rid="B7">Angara et&#xa0;al., 2016</xref>).</p>
<p>In addition, Yi et&#xa0;al. demonstrated that exosomes derived from miR-30b-3p overexpressing-MSCs by serum amyloid A3 (SAA3) inhibition can lead to protection against LPS-induced ALI (<xref ref-type="bibr" rid="B201">Yi et&#xa0;al., 2019</xref>). The SAA3 protein is one of the mediators of TLR4 signaling. Based on findings, LPS induced alveolar epithelial cells (AEC) apoptosis could be inhibited by downregulating the expression of SAA3 via overexpressing miR-30b-3p. Overall, SAA3 binding to myeloid differentiation factor 2 (MD-2) activates the NF-kB pathway in a MyD88-dependent manner. When Gram-negative bacteria contain LPS, the TLR4/MD-2 complex recognizes it and triggers an innate immune response (<xref ref-type="bibr" rid="B201">Yi et&#xa0;al., 2019</xref>; <xref ref-type="bibr" rid="B73">Jiang et&#xa0;al., 2020</xref>).</p>
<p>Also, a study performed by Wang et&#xa0;al. showed that exosomes from AD-MSCs can suppress the progression of chronic endometritis (CE) (<xref ref-type="bibr" rid="B184">Wang et&#xa0;al., 2023</xref>). For this purpose, human endometrial stromal cells (hESCs) were used to create an <italic>in vitro</italic> CE and a mouse model with LPS-induced CE in vivo was used to assess the effectiveness of Exos derived from AD-MSCs in vivo (<xref ref-type="bibr" rid="B184">Wang et&#xa0;al., 2023</xref>). Generally, CE is an infectious and inflammatory disease associated with long-term, continuous and mild inflammation of the endometrium, which defined by the endometrium&#x2019;s stromal area becoming infiltrated by plasma cells (<xref ref-type="bibr" rid="B139">Puente et&#xa0;al., 2020</xref>). The findings showed that Exos extracted from AD-MSCs can be absorbed by hESCs, whereupon they promote proliferation and prevent apoptosis in hESCs exposed to LPS. Also, these exosomes led to the suppression of TNF-&#x3b1;, IL-6, and IL-1&#x3b2; expression in hESCs. Furthermore, exposure to AD-MSCs-derived exosomes suppressed LPS-stimulated inflammation in vivo. In addition, evaluations showed that endometrial cells, the miR-21/TLR4/NF-kB signaling pathway is how exosome reduce inflammation (<xref ref-type="bibr" rid="B184">Wang et&#xa0;al., 2023</xref>). Research has shown that miR-21 expression is considerably downregulated following an LPS challenge, suggesting that miR-21 is involved in the endometrial inflammatory response (<xref ref-type="bibr" rid="B68">Ibrahim et&#xa0;al., 2019</xref>). In recent study, it was also shown that exposure to LPS decreased miR-21 levels in hESCs, while administration of AD-MSCs-derived exosomes resulted in increased miR-21 expression (<xref ref-type="bibr" rid="B184">Wang et&#xa0;al., 2023</xref>). Based on reports, overexpression of miR-21 inactivates TLR4/NF-kB pathway by downregulation of TLR4 expression (<xref ref-type="bibr" rid="B101">Liu X-J. et&#xa0;al., 2023</xref>).</p>
<p>In another study by Wang et&#xa0;al., it was demonstrated that miR-223 in BM-MSCs-derived exosomes contributes to elicit cardio-protection effect in polymicrobial sepsis (<xref ref-type="bibr" rid="B182">Wang et&#xa0;al., 2015</xref>). According to the reports miR-223 is highly enriched in MSC-derived exosomes, which may be delivered to cardiomyocytes and cause downregulation of two known targets of miR-223: semaphorin 3A (Sema3A) and STAT3. This prevent sepsis-induced myocardial dysfunction by inhibiting the inflammatory response in macrophages and attenuating cardiomyocyte death during sepsis. Crucially, it has been demonstrated that Sema3A interact with TLRs, particularly TLR4, to start the cytokine storm that is triggered by sepsis (<xref ref-type="bibr" rid="B182">Wang et&#xa0;al., 2015</xref>).</p>
<p>In line with these studies, Zhao et&#xa0;al. showed that the poly(I:C), a TLR3 ligand, inhibits miR-143, which enhance immunosuppressive function and the therapeutic effect of MSCs on sepsis (<xref ref-type="bibr" rid="B212">Zhao et&#xa0;al., 2014</xref>). Of course, this activity can also be observed in exosomes derived from these cells. In their study, they demonstrated that after treating hUC-MSCs with poly(I:C) as TLR3 ligand, the MSCs&#x2019; anti-inflammatory effect on macrophages can be enhanced. Experiments confirmed that expression of miR-143 was greatly decreased in MSCs treated with poly(I:C), and that the expression level of miR-143 could control the impact of poly(I:C) on the immunosuppressive capacity of MSCs (<xref ref-type="bibr" rid="B212">Zhao et&#xa0;al., 2014</xref>).</p>
<p>It has been shown that MSC-Exo mediate polarization of macrophages from M1 to M2-like phenotype (<xref ref-type="bibr" rid="B173">Teo et&#xa0;al., 2023</xref>). Naive macrophages (M0) can be polarized into two different functional subsets in response to microenvironmental stimuli, pro-inflammatory M1 and anti-inflammatory M2 macrophages (<xref ref-type="bibr" rid="B149">Ruytinx et&#xa0;al., 2018</xref>). Pro-inflammatory factors such as TNF-&#x3b1;, IL-1&#x3b2;, IL-6, NO, and proteolytic enzymes, which cause inflammation and increase tissue damage, are produced by M1 phenotype macrophages that are polarized by inflammatory mediators like PAMPs such as LPS. Nonetheless, IL-4 or IL-13 can stimulate M2 macrophages to release immunosuppressive factors such as IL-10, Arg1, transforming growth factor (TGF)-&#x3b2;, IL-1RN, which help to maintain tissue homeostasis and promote healing (<xref ref-type="bibr" rid="B11">Atri et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B160">Shapouri-Moghaddam et&#xa0;al., 2018</xref>). In addition, observations show that MSC-derived exosomes can lead to immunosuppression by regulatory T cells (Tregs) (<xref ref-type="bibr" rid="B142">Qian et&#xa0;al., 2021</xref>). Tregs are able to inhibit proliferation of T cells and cytokine production and they are essential in preventing inflammation related to infectious diseases like sepsis and ALI (<xref ref-type="bibr" rid="B157">Schmidt et&#xa0;al., 2012</xref>). Despite the fact that the precise mechanism by which MSCs-Exos affect macrophage polarization remains unclear, it has been demonstrated that the activation of MyD88-dependent TLR signaling pathway, mediated by TLR4, induces the M2 phenotype in both murine and human monocytes through the extra domain A-fibronectin (EDA-FN) (<xref ref-type="bibr" rid="B173">Teo et&#xa0;al., 2023</xref>). Research has indicated that miRNAs contribute to macrophage polarization through MSCs-Exos interactions (<xref ref-type="bibr" rid="B39">Essandoh et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B159">Self-Fordham et&#xa0;al., 2017</xref>). It has been reported that exosomes generated from mouse mesenchymal stem cells use miR-21-5p to induce M2 phenotype of RAW264.7 cells (<xref ref-type="bibr" rid="B100">Liu et&#xa0;al., 2022</xref>). Also, exosomes derived from hUC-MSCs enhance M2 macrophage polarization mediated by miR-24-3p (<xref ref-type="bibr" rid="B62">Hou et&#xa0;al., 2023</xref>). Similarly, Lin et&#xa0;al. showed that through M2 macrophage polarization, exosomal miR-7704 from mesenchymal stromal cells can modulate a LPS-induced murine ALI model (<xref ref-type="bibr" rid="B97">Lin et&#xa0;al., 2023</xref>). According to their findings, the most prevalent and potent miRNA for encouraging macrophages to adopt the M2 phenotype is miR-7704, which also causes M2 polarization by blocking the MyD88/STAT1 signaling pathway (<xref ref-type="bibr" rid="B97">Lin et&#xa0;al., 2023</xref>). Intratracheal delivery of exosomes containing miR-7704 proved that these exosomes significantly induced M2 polarization in lung macrophages, thereby effectively restoring lung function and increasing survival (<xref ref-type="bibr" rid="B97">Lin et&#xa0;al., 2023</xref>). It should be noted that M1/M2 polarization is determined by the balance of members of STAT (signal transducers and activators of transcription) family. It is commonly acknowledged that one of the primary mediators of inflammatory responses is STAT1. When LPS is bound, TLR4 is usually activated first, which is followed by the phosphorylation of STAT1. Upstream MyD88 activation is necessary for this signal transduction to occur (<xref ref-type="bibr" rid="B175">Tugal et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B185">Wang et&#xa0;al., 2014</xref>).</p>
<p>Similar to these findings, Ti et&#xa0;al. have also shown that the resolution of chronic inflammation can be achieved through the manipulation of macrophage polarization by LPS-preconditioned mesenchymal stromal cells (LPS pre-MSCs) through the exosome-shuttled miR-let-7b (<xref ref-type="bibr" rid="B174">Ti et&#xa0;al., 2015</xref>). In this regard, <italic>in vitro</italic> evaluations for the expression of inflammation cytokines and the distribution of macrophage subtype were performed using human monocytic cell line THP-1, which were treated with LPS pre-hUC-MSCs exosomes and were exposed to high glucose as an inflammatory model. When compared to untreated MSC-derived exosomes (un-Exo), LPS pre-Exo demonstrated a great capacity to modulate upregulation of anti-inflammatory cytokines expression and promotion of M2 macrophage activation (<xref ref-type="bibr" rid="B174">Ti et&#xa0;al., 2015</xref>). Exosome analysis revealed the unique presence of miR-let-7b in LPS pre-Exo compared to un-Exo and the potential role of the miR-let-7b/TLR4 pathway in promoting reduced inflammation and macrophage polarization. Additional exploration of the mechanisms governing the expression of miR-let-7b revealed that the regulation of macrophage polarization is significantly influenced by the TLR4/NF-kB/STAT3 signaling pathway (<xref ref-type="bibr" rid="B174">Ti et&#xa0;al., 2015</xref>).</p>
<p>In addition, Song et&#xa0;al. demonstrated that exosomal miR-146a enhances the therapeutic efficacy of IL-1&#x3b2;-primed MSCs in the treatment of sepsis (<xref ref-type="bibr" rid="B166">Song et&#xa0;al., 2017</xref>). They assessed the therapeutic effects of IL-1&#x3b2;, a pro-inflammatory cytokine that is abundant in the early stages of sepsis, as a pretreatment for hUC-MSCs in a model of sepsis brought on by cecal ligation and puncture (CLP) (<xref ref-type="bibr" rid="B166">Song et&#xa0;al., 2017</xref>). Comparing &#x3b2;MSCs to naive MSCs, the findings showed that systemic administration of IL-1&#x3b2;-pretreated MSCs (&#x3b2;MSCs) improved the symptoms of murine sepsis and increased the survival rate more effectively. Moreover, they showed that macrophage polarization towards the anti-inflammatory M2 phenotype can be more effectively induced by the paracrine activity of &#x3b2;MSCs (<xref ref-type="bibr" rid="B166">Song et&#xa0;al., 2017</xref>). According to the findings, &#x3b2;MSC-derived exosomes play an effective role in regulating this process. They discovered IL-1&#x3b2; stimulation significantly increased the expression of well-known anti-inflammatory microRNA, miR-146a, which was then specifically packaged into exosomes. Evaluations showed that this exosomal miR-146a upon translocation to macrophages, induced M2 polarization and as a result, improved survival in septic mice (<xref ref-type="bibr" rid="B166">Song et&#xa0;al., 2017</xref>). Conversely, when miR-146a is inhibited via transfection with miR-146a inhibitors, the regulatory characteristics of exosomes derived from &#x3b2;MSC are diminished. TLR agonists like IL-1&#x3b2; and TNF-&#x3b1; can trigger the expression of miR-146a, which then suppresses inflammation by targeting immune cells&#x2019; IRAK1, TRAF6, and interferon regulatory factor 5 (IRF5) (<xref ref-type="bibr" rid="B166">Song et&#xa0;al., 2017</xref>). Moreover, based on reports, high levels of miR-146a has protective effect against ALI by downregulation of TLR4 activity (<xref ref-type="bibr" rid="B104">Luo et&#xa0;al., 2018</xref>).</p>
<p>Based on many studies, sepsis is one of the most important complications of bacterial infection, which leads to death in many cases. As mentioned in some of the above studies, the complications of sepsis are influenced by miRNAs and their interactions with TLRs. In <xref ref-type="table" rid="T4">
<bold>Table&#xa0;4</bold>
</xref>, some miRNAs and their intraction and regulatory effect on TLRs in sepsis are listed.</p>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>Some microRNAs related to sepsis and their regulatory effect on infection by affecting the TLR signaling pathway.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">miRNAs</th>
<th valign="middle" align="center">Target</th>
<th valign="middle" align="center">Function</th>
<th valign="middle" align="center">Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">miR-150</td>
<td valign="middle" align="center">TLR2TLR7/TLRs signaling</td>
<td valign="middle" align="center">-Main regulator of immune cell activation and differentiation<break/>-Adjusts the TLR2 level by blocking the MY-D88, which ultimately leads to regulation of inflammation.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B196">Xu et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B164">Shomali et&#xa0;al., 2022</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-146a</td>
<td valign="middle" align="center">TLR4/TLRs signaling</td>
<td valign="middle" align="center">-miR-146a could reduce the NFkB activation pathway via directly targeting TRAF6, so the production of inflammatory cytokine and chemokines is down-regulated.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B120">Nahid et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B169">Szil&#xe1;gyi et&#xa0;al., 2019</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-223</td>
<td valign="middle" align="center">TLRs signaling</td>
<td valign="middle" align="center">-Regulates NF-&#x3ba;B signaling pathway via inhibiting p65 phosphorylation.<break/>-The low expression of miR-223 leads to the activation of the NF-&#x3ba;B signaling pathway and production of inflammatory factors.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B14">Benz et&#xa0;al., 2015</xref>; <xref ref-type="bibr" rid="B203">Zhang et&#xa0;al., 2017</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-155</td>
<td valign="middle" align="center">TLRs signaling</td>
<td valign="middle" align="center">-The activation of miR-155 leads to the suppression of negative regulators of inflammation.<break/>-miR-155 via inhibiting some effectors such SOCS1 and SHIP1 activates NF-KB, which leads to inflammation.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B162">Shim et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B28">Colbert et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B135">Pfeiffer et&#xa0;al., 2017</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-182</td>
<td valign="middle" align="center">TLR4/TLRs signaling</td>
<td valign="middle" align="center">-The high expression of this microRNA can active TLR recognition via MYD-88 pathway, which causes activation of APC cells. This activation leads to cytokines secretion and activation of Th1 and Th17 cells.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B111">Meydan et&#xa0;al., 2018</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-342</td>
<td valign="middle" align="center">TLR4/TLRs signaling</td>
<td valign="middle" align="center">-miR-342-5p regulates miR-155 positively.<break/>-The up-regulation of miR-155 in activated APC cells promote inflammation.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B178">Vasilescu et&#xa0;al., 2009</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-15a</td>
<td valign="middle" align="center">TLR4/TLRs signaling</td>
<td valign="middle" align="center">-miR-15a is involved in TLR4 expression and regulation of macrophage phagocytosis.<break/>-The upregulated miR-15a reduces the LPS-induced inflammatory pathways.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B186">Wang et&#xa0;al., 2018</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-574-5p</td>
<td valign="middle" align="center">TLR9/TLRs signaling</td>
<td valign="middle" align="center">-miR-574-5p has a relationship with TLR9.<break/>-It directly targets checkpoint suppressor 1 (Ches1) which is involved in TLR9 regulation.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B94">Li et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B208">Zhang Z-J. et&#xa0;al., 2020</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">Let-7</td>
<td valign="middle" align="center">TLR4/TLRs signaling</td>
<td valign="middle" align="center">-Let-7a acts as a TLR4 antagonist.<break/>-Let-7a is correlated with reduced TNF alpha, interleukin1&#x3b2;, and TLR signaling in an LPS-induced manner.<break/>-Levels of let-7a is associated with the regulation of the TLR-mediated immune response in sepsis.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B63">How et&#xa0;al., 2015</xref>; <xref ref-type="bibr" rid="B135">Pfeiffer et&#xa0;al., 2017</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-200</td>
<td valign="middle" align="center">TLR4/TLRs signaling</td>
<td valign="middle" align="center">-The miR-200 family are included miR-200b, 200a-429, and miR-200 c-141, which regulate TLR-mediated NF-&#x3ba;B activation.<break/>-The miR-200b and miR-200c are involved in regulating TLR4 via downregulation of the MyD88 expression.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B192">Wendlandt et&#xa0;al., 2012</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-149</td>
<td valign="middle" align="center">TLRs signaling</td>
<td valign="middle" align="center">-High expression of miR-149 decreases MyD88 protein expression and production of inflammation inducers such as TNF-&#x3b1;, IL-6, and NF-&#x3ba;B in response to LPS stimulation<break/>-miR-149 is able to directly target the 3&#x2032;-UTR of MyD88 mRNA.<break/>-This micoRNA via regulating TLR/MyD88 signaling pathway has an important immunomodulatory role in sepsis pathogenesis.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B197">Xu et&#xa0;al., 2014</xref>)</td>
</tr>
<tr>
<td valign="middle" align="center">miR-203</td>
<td valign="middle" align="center">TLRs signaling</td>
<td valign="middle" align="center">-This microRNA negatively regulates TLRs.<break/>-The up-regulation of miR203 leads to reduced MyD88 expression, which causes suppression of pro-inflammatory factors<break/>-miR-203 changed macrophage polarization from M1 to M2.</td>
<td valign="middle" align="center">(<xref ref-type="bibr" rid="B190">Wei et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B10">Arenas-Padilla and Mata-Haro, 2018</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Studies have also shown that exosome/microRNA-based therapies can be a potentially effective treatment against viral infections such as SARS-CoV-2 (<xref ref-type="bibr" rid="B80">Keshavarz et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B131">Paul et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B106">Mao et&#xa0;al., 2023</xref>). During viral infection macrophages as a member of the mononuclear phagocyte system (MPS), play a crucial role in the innate immune response against viruses by bridging the innate and adaptive immune responses via antigen presentation to T cells (<xref ref-type="bibr" rid="B158">Schultz et&#xa0;al., 2021</xref>). In COVID-19 infection, activation of macrophages leads to induced production and secretion of type I interferon cytokines such as IL-6 and TNF (<xref ref-type="bibr" rid="B110">Merad and Martin, 2020</xref>), which can induce the expression of angiotensin-converting enzyme 2 (ACE2). The ACE2 is a spike protein receptor, which facilities SARS-CoV-2 entry to the macrophage cytoplasm. In this process, the TLRs can recognize viral genetic material such as miRNAs and induce the innate immune response (<xref ref-type="bibr" rid="B102">Loo and Gale, 2011</xref>). For instance, SARS-CoV-2 is recognized by TLR7 which is essential in the defense against viral infections by activation of the MyD88 pathways and ultimately increases TNF&#x3b1;, IL-1&#x3b2;, IL-6, IL-12, and IFN&#x3b1; expression. In addition, TLR3 and TLR4 active several factors such as TNF receptor-associated factor, interferon regulatory factor 3 (IFR3), and NF-kB, which finally induce the production of type I, IFN&#x3b1;/&#x3b2; (<xref ref-type="bibr" rid="B69">Iqbal et&#xa0;al., 2020</xref>). Furthermore, TLR4 can bind to the spike protein and amplify the inflammatory responses. Studies have shown that host exosomal miRNAs are actively involved in the process of viral infection. In addition, viral miRNAs can also cause extensive changes in the host transcriptome. It was shown that different types of miRNA through TLRs have a vital role in regulating the function of different types of immune cells and host immune homeostasis during viral infection. Therefore, considering the importance of miRNAs in host-pathogen interactions, these small molecules can be considered as modulators of viral infection. In this regards, in a bioinformatics based-study by <xref ref-type="bibr" rid="B158">Schultz et&#xa0;al. (2021)</xref>, it was investigated whether miRNA cargoes in MSC-derived exosomes have the capacity to modulate the exacerbated cytokines and cell death in severe COVID-19. Accordingly, three datasets of miRNA using different stem cell tissue sources including bone marrow, umbilical cord and adipose tissue were analyzed. Their findings showed that based on cell sources, MSC-derived exosomes can carry different types of miRNA, the most important of which are miR-125a-3p, miR-125b-3p, miR-202-3p, and miR-769-3p. These miRNAs can decrease the production of inflammatory cytokines and minimize cell death by targeting the corresponding 3&#x2032;-UTRs of multiple mRNAs and TLR pathways such as TLR7/NF-kB signaling. In general, the mechanism of exosomal miRNAs effect on cytokine storm in COVID-19 take place in different ways, the most important of which is to reduce the level of chemokines and pro-inflammatory cytokines through the release of IL-1 receptor agonist, secreting the anti-inflammatory protein TNF-&#x3b1;&#x2013;stimulated gene 6 protein (TSG-6), and finally, downregulating NF-kB signaling in a TLRs-dependent signaling pathway (<xref ref-type="bibr" rid="B82">Kiaie et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B29">Csobonyeiova et&#xa0;al., 2023</xref>). On the other hand, it has also been shown that the use of miRNA can be effective in controlling HIV infections. Based on the reports, apart from host miRNAs, the HIV genome encodes viral miRNAs, most of which belong to the trans-activation response element (TAR) group. It has also been shown that exosomal TAR miRNA can upregulate the expression of inflammatory factors, especially IL-6 and TNF-&#x3b2;, which can result from the binding of TLRs to TAR miRNA. This subsequently activates the NF-&#x3ba;B pathway to accelerate the production of cytokines against HIV virus (<xref ref-type="bibr" rid="B153">Sampey et&#xa0;al., 2016</xref>).</p>
<p>Finally, although the effective role of stem cells and exosomes in regulating immune responses in infectious diseases has been shown in many studies, a paradigm has been presented by Waterman et&#xa0;al. that shows the polarization effects of TLR3 and TLR4 on the MSCs (<xref ref-type="bibr" rid="B189">Waterman et&#xa0;al., 2010</xref>). According to their model, the MSCs developed into two different phenotypes, MSC1 and MSC2, as a result of the activation of these receptors. This theory suggests that the concentrations of two inflammatory mediators, such as TNF-&#x3b1; and IFN-&#x3b3;, can cause MSCs and subsequently monocytes, to polarize into two different phenotypes (<xref ref-type="bibr" rid="B189">Waterman et&#xa0;al., 2010</xref>). When levels of these mediators and LPS as TLR4 specific ligands are lower, MSCs adopt a pro-inflammatory phenotype referred to as MSC1. This leads to the activation of T cell and recruitment of inflammatory cells to the sites of damage by releasing chemokineslike IP-10 (CXCL10), MIP-1&#x3b1;, MIP-1&#x3b2;, RANTES, and CXCL9. TGF-&#x3b2; and IL-6 are always expressed by MSCs. On the other hand, when levels of TNF-&#x3b1;, IFN-&#x3b3;, and ds-RNA as TLR3 specific ligand, and TGF-&#x3b2;1 are high, MSCs switch to MSC2 phenotype, which promotes the development of Treg. As a result, insufficient levels of TNF-&#x3b1; and IFN-&#x3b3; appear to enhance the pro-inflammatory phenotypes of MSCs (<xref ref-type="bibr" rid="B189">Waterman et&#xa0;al., 2010</xref>). Consequently, the complete molecular cascade of MSCs can take place during various phases of inflammation and still perform their intended role (<xref ref-type="bibr" rid="B51">Gholizadeh-Ghaleh Aziz et&#xa0;al., 2021</xref>). MSC2 has a significant function in stimulating the immune system of the host, which thereby completing the cycle of preventing tissue damage and promoting tissue repair. Generally speaking, MSC&#x2019;s immunomodulatory potential may be increased by TLR3 activation while it may be decreased by TLR4 activation. Therefore, depending on the type of receptors, ligands and cell sources, TLR-priming MSCs can initiate distinct signaling pathways in varying stages of the inflammation and in different types of immune cells. As a result, the hypothesis of Waterman et&#xa0;al. offers a novel perspective on how MSC-based treatments are developed (<xref ref-type="bibr" rid="B189">Waterman et&#xa0;al., 2010</xref>). So, further investigations are needed to elucidate how additional pro-inflammatory and anti-inflammatory factors are expressed in the TLR signaling pathway.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>The discovery that exosomes derived from stem cells can exhibit similar functions to stem cells has led to increased interest towards using exosomes in the treatment of diseases based on cell therapy without recruiting stem cells. Due to their small size and lack of replication capacity, exosomes are far less immunogenic and tumorigenic than stem cells. Thus, exosomes are generally more efficacious and safer than stem cells. Exosomes, therefore, have a great deal of potential uses and are frequently employed in stem cell-based therapeutic procedures. Numerous studies have shown that TLRs play a significant role in regulating immune responses during infection based on HDT, and therefore targeting TLR signaling pathways as new approach for controlling infectious diseases has been considered. During infection, it has been demonstrated that stem cells and stem cells-derived exosomes have immunomodulatory and immunosuppressive activities, which in most of them, TLRs are the main mediators. As indicated in this review, one of the most significant exosome cargoes is miRNAs and it has been discovered that these miRNAs frequently regulate TLR activity, which contributes to therapeutic effect of exosomes. Findings have shown that miRNAs in MSCs-derived exosomes have significant effects on inflammatory and non-inflammatory diseases. However, these miRNAs and their downstream pathway/target genes have great diversity. This diversity necessitates comprehensive research on miRNAs and also other cargoes in MSC-Exos. Even though it is commonly known that MSC-Exos can treat infectious diseases, it is crucial to identify which exosome components are most important in order to better understand the mechanism of disease treatment. Furthermore, these exosomes can be altered to carry various cargoes and drugs including miRNAs and their surface-specific receptors can be synthetically modified to facilitate the transfer of exosomes to target cells.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>MM: Conceptualization, Data curation, Investigation, Writing&#xa0;&#x2013;&#xa0;original draft, Writing &#x2013; review &amp; editing. EB: Data curation, Investigation, Writing &#x2013; review &amp; editing. HS: Investigation, Writing &#x2013; original draft, Data curation. ZG: Data curation, Investigation, Writing &#x2013; original draft. RK: Investigation, Writing &#x2013; original draft. MH: Visualization, Writing &#x2013; original draft. IF: Conceptualization, Supervision, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdi</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Rashedi</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Keating</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Concise review: TLR pathway-miRNA interplay in mesenchymal stromal cells: regulatory roles and therapeutic directions</article-title>. <source>Stem Cells</source> <volume>36</volume>, <fpage>1655</fpage>&#x2013;<lpage>1662</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/stem.2902</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Kahlert</surname> <given-names>U. D.</given-names>
</name>
<name>
<surname>Niemel&#xe4;</surname> <given-names>M.</given-names>
</name>
<name>
<surname>H&#xe4;nggi</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Chaudhry</surname> <given-names>S. R.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Role of adaptor protein myeloid differentiation 88 (MyD88) in post-subarachnoid hemorrhage inflammation: A systematic review</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>, <fpage>4185</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms22084185</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akira</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Hemmi</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Recognition of pathogen-associated molecular patterns by TLR family</article-title>. <source>Immunol. lett.</source> <volume>85</volume>, <fpage>85</fpage>&#x2013;<lpage>95</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0165-2478(02)00228-6</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali Imani Fooladi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Fazlollah Mousavi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Seghatoleslami</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Yazdani</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Reza Nourani</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Toll-like receptors: role in inflammation and commensal bacteria</article-title>. <source>Inflammation Allergy-Drug Targets (Formerly Curr. Drug Targets-Inflamm. Allergy)(Discontinued).</source> <volume>10</volume>, <fpage>198</fpage>&#x2013;<lpage>207</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/187152811795564064</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alivernini</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Gremese</surname> <given-names>E.</given-names>
</name>
<name>
<surname>McSharry</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Tolusso</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Ferraccioli</surname> <given-names>G.</given-names>
</name>
<name>
<surname>McInnes</surname> <given-names>I. B.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>MicroRNA-155&#x2014;at the critical interface of innate and adaptive immunity in arthritis</article-title>. <source>Front. Immunol.</source> <volume>8</volume>, <elocation-id>1932</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2017.01932</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amarante-Mendes</surname> <given-names>G. P.</given-names>
</name>
<name>
<surname>Adjemian</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Branco</surname> <given-names>L. M.</given-names>
</name>
<name>
<surname>Zanetti</surname> <given-names>L. C.</given-names>
</name>
<name>
<surname>Weinlich</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Bortoluci</surname> <given-names>K. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Pattern recognition receptors and the host cell death molecular machinery</article-title>. <source>Front. Immunol.</source> <volume>9</volume>, <elocation-id>2379</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.02379</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angara</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Syed</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Das</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Jan&#xe9;r</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Pryhuber</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Rahman</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Inhibition of RPTOR prevents hyperoxia-induced lung injury by enhancing autophagy and reducing apoptosis in neonatal mice</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source> <volume>55</volume>, <fpage>722</fpage>&#x2013;<lpage>735</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1165/rcmb.2015-0349OC</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anwar</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Recent clinical trends in Toll-like receptor targeting therapeutics</article-title>. <source>Medicinal Res. Rev.</source> <volume>39</volume>, <fpage>1053</fpage>&#x2013;<lpage>1090</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/med.21553</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arabpour</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Saghazadeh</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Rezaei</surname> <given-names>N.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Anti-inflammatory and M2 macrophage polarization-promoting effect of mesenchymal stem cell-derived exosomes</article-title>. <source>Int. immunopharmacol.</source> <volume>97</volume>, <fpage>107823</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2021.107823</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arenas-Padilla</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Mata-Haro</surname> <given-names>V.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Regulation of TLR signaling pathways by microRNAs: implications in inflammatory diseases</article-title>. <source>Cent. Eur. J. Immunol.</source> <volume>43</volume>, <fpage>482</fpage>&#x2013;<lpage>489</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.5114/ceji.2018.81351</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atri</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Guerfali</surname> <given-names>F. Z.</given-names>
</name>
<name>
<surname>Laouini</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Role of human macrophage polarization in inflammation during infectious diseases</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume>, <fpage>1801</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms19061801</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baumann</surname> <given-names>C. L.</given-names>
</name>
<name>
<surname>Aspalter</surname> <given-names>I. M.</given-names>
</name>
<name>
<surname>Sharif</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Pichlmair</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Bl&#xfc;ml</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Grebien</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>CD14 is a coreceptor of Toll-like receptors 7 and 9</article-title>. <source>J. Exp. Med.</source> <volume>207</volume>, <fpage>2689</fpage>&#x2013;<lpage>2701</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20101111</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Behzadi</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Perdomo</surname> <given-names>H. A.</given-names>
</name>
<name>
<surname>Karpi&#x144;ski</surname> <given-names>T. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Toll-like receptors: general molecular and structural biology</article-title>. <source>J. Immunol. Res.</source> <volume>2021</volume>, <fpage>1</fpage>&#x2013;<lpage>21</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2021/9914854</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benz</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Tacke</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Luedde</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Trautwein</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Luedde</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Koch</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Circulating microRNA-223 serum levels do not predict sepsis or survival in patients with critical illness</article-title>. <source>Dis. mark.</source> <volume>2015</volume>:<fpage>384208</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2015/384208</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernard</surname> <given-names>G. R.</given-names>
</name>
<name>
<surname>Vincent</surname> <given-names>J.-L.</given-names>
</name>
<name>
<surname>Laterre</surname> <given-names>P.-F.</given-names>
</name>
<name>
<surname>LaRosa</surname> <given-names>S. P.</given-names>
</name>
<name>
<surname>Dhainaut</surname> <given-names>J.-F.</given-names>
</name>
<name>
<surname>Lopez-Rodriguez</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2001</year>). <article-title>Efficacy and safety of recombinant human activated protein C for severe sepsis</article-title>. <source>New Engl. J. Med.</source> <volume>344</volume>, <fpage>699</fpage>&#x2013;<lpage>709</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJM200103083441001</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boosani</surname> <given-names>C. S.</given-names>
</name>
<name>
<surname>Agrawal</surname> <given-names>D. K.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Epigenetic regulation of innate immunity by microRNAs</article-title>. <source>Antibodies</source> <volume>5</volume>, <fpage>8</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/antib5020008</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bosch</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Young</surname> <given-names>N. A.</given-names>
</name>
<name>
<surname>Mignot</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Bach</surname> <given-names>J.-M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Epigenetic mechanisms in immune disease: the significance of toll-like receptor-binding extracellular vesicle-encapsulated microRNA</article-title>. <source>Front. Genet.</source> <volume>11</volume>, <elocation-id>578335</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2020.578335</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bz&#xf3;wka</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Bagrowska</surname> <given-names>W.</given-names>
</name>
<name>
<surname>G&#xf3;ra</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Recent advances in studying Toll-like receptors with the use of computational methods</article-title>. <source>J. Chem. Inf. Model</source> <volume>12</volume>, <fpage>3669</fpage>&#x2013;<lpage>3687</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acs.jcim.3c00419</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname> <given-names>Z.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Important aspects of Toll-like receptors, ligands and their signaling pathways</article-title>. <source>Inflammation Res.</source> <volume>59</volume>, <fpage>791</fpage>&#x2013;<lpage>808</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00011-010-0208-2</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname> <given-names>Y.-M.</given-names>
</name>
<name>
<surname>Chou</surname> <given-names>Y.-T.</given-names>
</name>
<name>
<surname>Kan</surname> <given-names>W.-C.</given-names>
</name>
<name>
<surname>Shiao</surname> <given-names>C.-C.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Sepsis and acute kidney injury: A review focusing on the bidirectional interplay</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>, <fpage>9159</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms23169159</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Rong</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Expression and role of Toll-like receptors on human umbilical cord mesenchymal stromal cells</article-title>. <source>Cytotherapy</source> <volume>15</volume>, <fpage>423</fpage>&#x2013;<lpage>433</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jcyt.2012.12.001</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>X.-M.</given-names>
</name>
<name>
<surname>Splinter</surname> <given-names>P. L.</given-names>
</name>
<name>
<surname>O'Hara</surname> <given-names>S. P.</given-names>
</name>
<name>
<surname>LaRusso</surname> <given-names>N. F.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection</article-title>. <source>J. Biol. Chem.</source> <volume>282</volume>, <fpage>28929</fpage>&#x2013;<lpage>28938</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M702633200</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mechanism of cargo sorting into small extracellular vesicles</article-title>. <source>Bioengineered</source> <volume>12</volume>, <fpage>8186</fpage>&#x2013;<lpage>8201</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21655979.2021.1977767</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mesenchymal stem cell-derived extracellular vesicles: a novel cell-free therapy for sepsis</article-title>. <source>Front. Immunol.</source> <volume>11</volume>, <elocation-id>647</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.00647</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname> <given-names>K.-A.</given-names>
</name>
<name>
<surname>Cha</surname> <given-names>J.-E.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>Y.-H.</given-names>
</name>
<name>
<surname>Ryu</surname> <given-names>K.-H.</given-names>
</name>
<name>
<surname>Woo</surname> <given-names>S.-Y.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Mesenchymal stem cell-derived exosomes attenuate TLR7-mediated mast cell activation</article-title>. <source>Tissue Eng. Regen. Med.</source> <volume>19</volume> (<issue>1</issue>), <fpage>117</fpage>&#x2013;<lpage>129</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s13770-021-00395-4</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chousterman</surname> <given-names>B. G.</given-names>
</name>
<name>
<surname>Swirski</surname> <given-names>F. K.</given-names>
</name>
<name>
<surname>Weber</surname> <given-names>G. F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Cytokine storm and sepsis disease pathogenesis</article-title>. <source>Semin. Immunopathol</source> <volume>39</volume> (<issue>5</issue>), <fpage>517</fpage>&#x2013;<lpage>528</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00281-017-0639-8</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname> <given-names>I. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>The advent of the cytokine storm</article-title>. <source>Immunol. Cell Biol.</source> <volume>85</volume>, <fpage>271</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/sj.icb.7100062</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colbert</surname> <given-names>J. F.</given-names>
</name>
<name>
<surname>Ford</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Haeger</surname> <given-names>S. M.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Dailey</surname> <given-names>K. L.</given-names>
</name>
<name>
<surname>Allison</surname> <given-names>K. C.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>A model-specific role of microRNA-223 as a mediator of kidney injury during experimental sepsis</article-title>. <source>Am. J. Physiology-Renal Physiol.</source> <volume>313</volume>, <fpage>F553</fpage>&#x2013;<lpage>F5F9</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/ajprenal.00493.2016</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Csobonyeiova</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Smolinska</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Harsanyi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Ivantysyn</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Klein</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The immunomodulatory role of cell-free approaches in SARS-coV-2-induced cytokine storm&#x2014;A powerful therapeutic tool for COVID-19 patients</article-title>. <source>Biomedicines</source> <volume>11</volume>, <fpage>1736</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/biomedicines11061736</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deguine</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Barton</surname> <given-names>G. M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>MyD88: a central player in innate immune signaling</article-title>. <source>F1000prime Rep.</source> <volume>6</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.12703/P</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Kraker</surname> <given-names>M. E.</given-names>
</name>
<name>
<surname>Stewardson</surname> <given-names>A. J.</given-names>
</name>
<name>
<surname>Harbarth</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Will 10 million people die a year due to antimicrobial resistance by 2050</article-title>? <source>PloS Med.</source> <volume>13</volume>, <elocation-id>e1002184</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pmed.1002184</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dias</surname> <given-names>M. L.</given-names>
</name>
<name>
<surname>O&#x2019;Connor</surname> <given-names>K. M.</given-names>
</name>
<name>
<surname>Dempsey</surname> <given-names>E. M.</given-names>
</name>
<name>
<surname>O&#x2019;Halloran</surname> <given-names>K. D.</given-names>
</name>
<name>
<surname>McDonald</surname> <given-names>F. B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Targeting the Toll-like receptor pathway as a therapeutic strategy for neonatal infection</article-title>. <source>Am. J. Physiology-Regul. Integr. Comp. Physiol.</source> <volume>321</volume>, <fpage>R879</fpage>&#x2013;<lpage>R902</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/ajpregu.00307.2020</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Gioia</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Zanoni</surname> <given-names>I.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Toll-like receptor co-receptors as master regulators of the immune response</article-title>. <source>Mol. Immunol.</source> <volume>63</volume>, <fpage>143</fpage>&#x2013;<lpage>152</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2014.05.008</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drobiova</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Sindhu</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Ahmad</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Haddad</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Al-Mulla</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Al Madhoun</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Wharton&#x2019;s jelly mesenchymal stem cells: A concise review of their secretome and prospective clinical applications</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcell.2023.1211217</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Du</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Xing</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H. Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>R.-F.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Toll-like receptor signaling and its role in cell-mediated immunity</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <elocation-id>812774</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.812774</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dudzik</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Macioszek</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Struck-Lewicka</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Kordalewska</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Buszewska-Forajta</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Waszczuk-Jankowska</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Perspectives and challenges in extracellular vesicles untargeted metabolomics analysis</article-title>. <source>TrAC Trends Anal. Chem.</source> <volume>143</volume>, <fpage>116382</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.trac.2021.116382</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Echchannaoui</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Frei</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Schnell</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Leib</surname> <given-names>S. L.</given-names>
</name>
<name>
<surname>Zimmerli</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Landmann</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Toll-like receptor 2&#x2013;deficient mice are highly susceptible to Streptococcus pneumoniae meningitis because of reduced bacterial clearing and enhanced inflammation</article-title>. <source>J. Infect. dis.</source> <volume>186</volume>, <fpage>798</fpage>&#x2013;<lpage>806</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1086/342845</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Zayat</surname> <given-names>S. R.</given-names>
</name>
<name>
<surname>Sibaii</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Mannaa</surname> <given-names>F. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Toll-like receptors activation, signaling, and targeting: an overview</article-title>. <source>Bull. Natl. Res. Centre.</source> <volume>43</volume>, <fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s42269-019-0227-2</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Essandoh</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Huo</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>G.-C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>MiRNA-mediated macrophage polarization and its potential role in the regulation of inflammatory response</article-title>. <source>Shock (Augusta Ga).</source> <volume>46</volume>, <fpage>122</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/SHK.0000000000000604</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Essola</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Mavoungou</surname> <given-names>J. F.</given-names>
</name>
<etal/>
</person-group>. (<year>2024</year>). <article-title>Exosome regulation of immune response mechanism: Pros and cons in immunotherapy</article-title>. <source>Bioactive Mater.</source> <volume>32</volume>, <fpage>124</fpage>&#x2013;<lpage>146</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bioactmat.2023.09.018</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabbri</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>TLRs as miRNA receptors</article-title>. <source>Cancer Res.</source> <volume>72</volume>, <fpage>6333</fpage>&#x2013;<lpage>6337</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3229</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farhat</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Riekenberg</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Heine</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Debarry</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Lang</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Mages</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2008</year>). <article-title>Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling</article-title>. <source>J. Leucocyte Biol.</source> <volume>83</volume>, <fpage>692</fpage>&#x2013;<lpage>701</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1189/jlb.0807586</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Febbraio</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Silverstein</surname> <given-names>R. L.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>CD36: implications in cardiovascular disease</article-title>. <source>Int. J. Biochem. Cell Biol.</source> <volume>39</volume>, <fpage>2012</fpage>&#x2013;<lpage>2030</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biocel.2007.03.012</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>B.</given-names>
</name>
<etal/>
</person-group>. (<year>2024</year>). <article-title>Interplay of energy metabolism and autophagy</article-title>. <source>Autophagy</source> <volume>20</volume>, <fpage>4</fpage>&#x2013;<lpage>14</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/15548627.2023.2247300</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fern&#xe1;ndez-Messina</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Guti&#xe9;rrez-V&#xe1;zquez</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Rivas-Garc&#xed;a</surname> <given-names>E.</given-names>
</name>
<name>
<surname>S&#xe1;nchez-Madrid</surname> <given-names>F.</given-names>
</name>
<name>
<surname>de la Fuente</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Immunomodulatory role of microRNAs transferred by extracellular vesicles</article-title>. <source>Biol. Cell.</source> <volume>107</volume>, <fpage>61</fpage>&#x2013;<lpage>77</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/boc.201400081</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitzgerald</surname> <given-names>K. A.</given-names>
</name>
<name>
<surname>Kagan</surname> <given-names>J. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Toll-like receptors and the control of immunity</article-title>. <source>Cell</source> <volume>180</volume>, <fpage>1044</fpage>&#x2013;<lpage>1066</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.041</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fleshner</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Crane</surname> <given-names>C. R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Exosomes, DAMPs and miRNA: features of stress physiology and immune homeostasis</article-title>. <source>Trends Immunol.</source> <volume>38</volume>, <fpage>768</fpage>&#x2013;<lpage>776</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2017.08.002</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fore</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Budipranama</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Destiawan</surname> <given-names>R. A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>TLR10 and its role in immunity</article-title>. <source>Toll-Like Recept. Health Dis.</source> <volume>276</volume>, <fpage>161</fpage>&#x2013;<lpage>174</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/164_2021_541</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freund</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Eigenbrod</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Helm</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Dalpke</surname> <given-names>A. H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>RNA modifications modulate activation of innate toll-like receptors</article-title>. <source>Genes</source> <volume>10</volume>, <fpage>92</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/genes10020092</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerold</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Zychlinsky</surname> <given-names>A.</given-names>
</name>
<name>
<surname>de Diego</surname> <given-names>J. L.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>What is the role of Toll-like receptors in bacterial infections</article-title>? <source>Semin. Immunol.</source> doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.smim.2006.12.003</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gholizadeh-Ghaleh Aziz</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Alipour</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Ranjbarvan</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Azari</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Babaei</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Golchin</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Critical roles of TLRs on the polarization of mesenchymal stem cells for cell therapy of viral infections: a notice for COVID-19 treatment</article-title>. <source>Comp. Clin. pathol.</source> <volume>30</volume>, <fpage>119</fpage>&#x2013;<lpage>128</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00580-021-03209-0</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girkin</surname> <given-names>J. L.</given-names>
</name>
<name>
<surname>Maltby</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Bartlett</surname> <given-names>N. W.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell</article-title>. <source>Eur. Respir. Review.</source> <volume>31</volume> (<issue>164</issue>), <fpage>210274</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1183/16000617.0274-2021</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giurini</surname> <given-names>E. F.</given-names>
</name>
<name>
<surname>Madonna</surname> <given-names>M. B.</given-names>
</name>
<name>
<surname>Zloza</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>K. H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Microbial-derived toll-like receptor agonism in cancer treatment and progression</article-title>. <source>Cancers</source> <volume>14</volume>, <fpage>2923</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers14122923</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goulopoulou</surname> <given-names>S.</given-names>
</name>
<name>
<surname>McCarthy</surname> <given-names>C. G.</given-names>
</name>
<name>
<surname>Webb</surname> <given-names>R. C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Toll-like receptors in the vascular system: sensing the dangers within</article-title>. <source>Pharmacol. Rev.</source> <volume>68</volume>, <fpage>142</fpage>&#x2013;<lpage>167</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1124/pr.114.010090</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grebe</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Hoss</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Latz</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>NLRP3 inflammasome and the IL-1 pathway in atherosclerosis</article-title>. <source>Circ. Res.</source> <volume>122</volume>, <fpage>1722</fpage>&#x2013;<lpage>1740</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.311362</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groot</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Sorting mechanisms for MicroRNAs into extracellular vesicles and their associated diseases</article-title>. <source>Cells</source> <volume>9</volume>, <fpage>1044</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells9041044</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guarino</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Perna</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Cesaro</surname> <given-names>A. E.</given-names>
</name>
<name>
<surname>Maritati</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Spampinato</surname> <given-names>M. D.</given-names>
</name>
<name>
<surname>Contini</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>2023 Update on sepsis and septic shock in adult patients: management in the emergency department</article-title>. <source>J. Clin. Med.</source> <volume>12</volume>, <fpage>3188</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/jcm12093188</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hajjar</surname> <given-names>A. M.</given-names>
</name>
<name>
<surname>Ernst</surname> <given-names>R. K.</given-names>
</name>
<name>
<surname>Fortuno</surname> <given-names>E. S.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Brasfield</surname> <given-names>A. S.</given-names>
</name>
<name>
<surname>Yam</surname> <given-names>C. S.</given-names>
</name>
<name>
<surname>Newlon</surname> <given-names>L. A.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica</article-title>. <source>PLoS Pathog.</source> <volume>8</volume> (<issue>10</issue>), <elocation-id>e1002963</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1002963</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Jing</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>MicroRNAs: new regulators of Toll-like receptor signalling pathways</article-title>. <source>BioMed. Res. Int.</source> <volume>2014</volume>:<fpage>945169</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2014/945169</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffman</surname> <given-names>B. A. J.</given-names>
</name>
<name>
<surname>Pumford</surname> <given-names>E. A.</given-names>
</name>
<name>
<surname>Enueme</surname> <given-names>A. I.</given-names>
</name>
<name>
<surname>Fetah</surname> <given-names>K. L.</given-names>
</name>
<name>
<surname>Friedl</surname> <given-names>O. M.</given-names>
</name>
<name>
<surname>Kasko</surname> <given-names>A. M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Engineered macromolecular Toll-like receptor agents and assemblies</article-title>. <source>Trends Biotechnol.</source> <volume>41</volume> (<issue>9</issue>), <fpage>P1139</fpage>&#x2013;<lpage>1154</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tibtech.2023.03.008</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname> <given-names>S.-Y.</given-names>
</name>
<name>
<surname>Teng</surname> <given-names>S.-W.</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C.-Y.</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>H.-I.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Allogeneic human umbilical cord-derived mesenchymal stem cells reduce lipopolysaccharide-induced inflammation and acute lung injury</article-title>. <source>Am. J. Trans. Res.</source> <volume>12</volume>, <fpage>6740</fpage>.</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>F.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>hUC-MSC-EV-miR-24 enhances the protective effect of dexmedetomidine preconditioning against myocardial ischemia&#x2013;reperfusion injury through the KEAP1/Nrf2/HO-1 signaling</article-title>. <source>Drug Delivery Trans. Res.</source> <volume>14</volume>(<issue>1</issue>):<page-range>143&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s13346-023-01388-7</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>How</surname> <given-names>C.-K.</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>S.-K.</given-names>
</name>
<name>
<surname>Shih</surname> <given-names>H.-C.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>M.-S.</given-names>
</name>
<name>
<surname>Chiou</surname> <given-names>S.-H.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>C.-H.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Expression profile of MicroRNAs in gram-negative bacterial sepsis</article-title>. <source>Shock</source> <volume>43</volume>, <fpage>121</fpage>&#x2013;<lpage>127</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/SHK.0000000000000282</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Drescher</surname> <given-names>K. M.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X.-M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Exosomal miRNAs: biological properties and therapeutic potential</article-title>. <source>Front. Genet.</source> <volume>3</volume>, <elocation-id>56</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2012.00056</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The cytokine storm and COVID-19</article-title>. <source>J. Med. virol.</source> <volume>93</volume>, <fpage>250</fpage>&#x2013;<lpage>256</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmv.26232</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>A.-Y.</given-names>
</name>
<name>
<surname>Eischeid</surname> <given-names>A. N.</given-names>
</name>
<name>
<surname>Dittman</surname> <given-names>J. W.</given-names>
</name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>MicroRNA-98 and let-7 confer cholangiocyte expression of cytokine-inducible Src homology 2-containing protein in response to microbial challenge</article-title>. <source>J. Immunol.</source> <volume>183</volume>, <fpage>1617</fpage>&#x2013;<lpage>1624</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.0804362</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>A bibliometric analysis of programmed cell death in acute lung injury/acute respiratory distress syndrome from 2000 to 2022</article-title>. <source>Heliyon</source> <volume>9</volume> (<issue>9</issue>), <elocation-id>e19759</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e19759</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibrahim</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Sz&#xf3;stek-Mioduchowska</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Skarzynski</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Expression profiling of selected miRNAs in equine endometrium in response to LPS challenge in <italic>vitro</italic>: A new understanding of the inflammatory immune response</article-title>. <source>Vet. Immunol. immunopathol.</source> <volume>209</volume>, <fpage>37</fpage>&#x2013;<lpage>44</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.vetimm.2019.02.006</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname> <given-names>M. S.</given-names>
</name>
<name>
<surname>Sardar</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Akmal</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Sultan</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Abdullah</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Qindeel</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Role of Toll-like receptors in Coronavirus infection and immune response</article-title>. <source>J Exp Biol.</source> <volume>8</volume> (<issue>Spl-1- SARS-CoV-2</issue>), <fpage>S66</fpage>&#x2013;<lpage>S78</lpage>.</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irvine</surname> <given-names>K. L.</given-names>
</name>
<name>
<surname>Hopkins</surname> <given-names>L. J.</given-names>
</name>
<name>
<surname>Gangloff</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Bryant</surname> <given-names>C. E.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6</article-title>. <source>Vet. Res.</source> <volume>44</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1297-9716-44-50</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isola A</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Exosomes: the messengers of health and disease</article-title>. <source>Curr. neuropharmacol.</source> <volume>15</volume>, <fpage>157</fpage>&#x2013;<lpage>165</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/1570159X14666160825160421</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaffer</surname> <given-names>U.</given-names>
</name>
<name>
<surname>Wade</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Gourlay</surname> <given-names>T.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Cytokines in the systemic inflammatory response syndrome: a review</article-title>. <source>HSR Proc. Intensive Care Cardiovasc. anesthesia.</source> <volume>2</volume>, <fpage>161</fpage>.</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Gui</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Procyanidin B2 suppresses lipopolysaccharides-induced inflammation and apoptosis in human type II alveolar epithelial cells and lung fibroblasts</article-title>. <source>J. Interferon Cytokine Res.</source> <volume>40</volume>, <fpage>54</fpage>&#x2013;<lpage>63</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/jir.2019.0083</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jim&#xe9;nez</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Cervantes-Garc&#xed;a</surname> <given-names>D.</given-names>
</name>
<name>
<surname>C&#xf3;rdova-D&#xe1;valos</surname> <given-names>L. E.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Rodr&#xed;guez</surname> <given-names>M. J.</given-names>
</name>
<name>
<surname>Gonzalez-Espinosa</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Salinas</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Responses of mast cells to pathogens: Beneficial and detrimental roles</article-title>. <source>Front. Immunol.</source> <volume>12</volume>, <elocation-id>685865</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.685865</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalluri</surname> <given-names>R.</given-names>
</name>
<name>
<surname>LeBleu</surname> <given-names>V. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The biology, function, and biomedical applications of exosomes</article-title>. <source>Science</source> <volume>367</volume>, <elocation-id>eaau6977</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aau6977</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname> <given-names>J. Y.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>J.-O.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Structural biology of the Toll-like receptor family</article-title>. <source>Annu. Rev. Biochem.</source> <volume>80</volume>, <fpage>917</fpage>&#x2013;<lpage>941</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-biochem-052909-141507</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufmann</surname> <given-names>S. H.</given-names>
</name>
<name>
<surname>Dorhoi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Hotchkiss</surname> <given-names>R. S.</given-names>
</name>
<name>
<surname>Bartenschlager</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Host-directed therapies for bacterial and viral infections</article-title>. <source>Nat. Rev. Drug discov.</source> <volume>17</volume>, <fpage>35</fpage>&#x2013;<lpage>56</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrd.2017.162</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Kawai</surname> <given-names>T.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Toll-like receptor signaling pathways</article-title>. <source>Front. Immunol.</source> <volume>5</volume>, <elocation-id>461</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2014.00461</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kellum</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Romagnani</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Ashuntantang</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Ronco</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Zarbock</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Anders</surname> <given-names>H.-J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Acute kidney injury</article-title>. <source>Nat. Rev. Dis. prime.</source> <volume>7</volume>, <fpage>52</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41572-021-00284-z</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keshavarz</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Dianat-Moghadam</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Sofiani</surname> <given-names>V. H.</given-names>
</name>
<name>
<surname>Karimzadeh</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Zargar</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Moghoofei</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>miRNA-based strategy for modulation of influenza A virus infection</article-title>. <source>Epigenomics</source> <volume>10</volume>, <fpage>829</fpage>&#x2013;<lpage>844</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2217/epi-2017-0170</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Pahari</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Vidyarthi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Aqdas</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Agrewala</surname> <given-names>J. N.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Stimulation through CD40 and TLR-4 is an effective host directed therapy against Mycobacterium tuberculosis</article-title>. <source>Front. Immunol.</source> <volume>7</volume>, <elocation-id>386</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2016.00386</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiaie</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Ghanavati</surname> <given-names>S. P. M.</given-names>
</name>
<name>
<surname>Miremadi</surname> <given-names>S. S.</given-names>
</name>
<name>
<surname>Hadipour</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Aghdam</surname> <given-names>R. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mesenchymal stem cell-derived exosomes for COVID-19 therapy, preclinical and clinical evidence</article-title>. <source>Int. J. Stem Cells</source> <volume>14</volume>, <fpage>252</fpage>&#x2013;<lpage>261</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.15283/ijsc20182</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>H.-J.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>J.-H.</given-names>
</name>
<name>
<surname>Hwangbo</surname> <given-names>C.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Toll-like receptor 4 (TLR4): new insight immune and aging</article-title>. <source>Immun. Age.</source> <volume>20</volume>, <fpage>67</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12979-023-00383-3</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kircheis</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Planz</surname> <given-names>O.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The role of toll-like receptors (TLRs) and their related signaling pathways in viral infection and inflammation</article-title>. <source>MDPI</source> <volume>24</volume> (<issue>7</issue>), <fpage>6701</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms24076701</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klekotka</surname> <given-names>P. A.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Yokoyama</surname> <given-names>W. M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Contrasting roles of the IL-1 and IL-18 receptors in MyD88-dependent contact hypersensitivity</article-title>. <source>J. Invest. Dermatol.</source> <volume>130</volume>, <fpage>184</fpage>&#x2013;<lpage>191</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/jid.2009.242</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kornilov</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Shabalkina</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Volynsky</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Kot</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Kayushin</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>The architecture of transmembrane and cytoplasmic juxtamembrane regions of Toll-like receptors</article-title>. <source>Nat. Commun.</source> <volume>14</volume>, <fpage>1503</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-023-37042-6</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname> <given-names>V.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Toll-like receptors in the pathogenesis of neuroinflammation</article-title>. <source>J. Neuroimmunol.</source> <volume>332</volume>, <fpage>16</fpage>&#x2013;<lpage>30</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jneuroim.2019.03.012</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname> <given-names>V.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets</article-title>. <source>Int. immunopharmacol.</source> <volume>89</volume>, <fpage>107087</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2020.107087</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Barrett</surname> <given-names>J. E.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Toll-Like Receptors (TLRs) in health and disease: An overview</article-title>. <source>Toll-like Recept. Health Dis.</source>, <fpage>1</fpage>&#x2013;<lpage>21</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-3-031-06512-5</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lafferty</surname> <given-names>E. I.</given-names>
</name>
<name>
<surname>Qureshi</surname> <given-names>S. T.</given-names>
</name>
<name>
<surname>Schnare</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>The role of toll-like receptors in acute and chronic lung inflammation</article-title>. <source>J. Inflamm.</source> <volume>7</volume>, <fpage>1</fpage>&#x2013;<lpage>14</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1476-9255-7-57</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Frevert</surname> <given-names>C. W.</given-names>
</name>
<name>
<surname>Matute-Bello</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Wurfel</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>V. A.</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>S.-M.</given-names>
</name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>TLR-4 pathway mediates the inflammatory response but not bacterial elimination in E. coli pneumonia</article-title>. <source>Am. J. Physiology-Lung Cell. Mol. Physiol.</source> <volume>289</volume>, <fpage>L731</fpage>&#x2013;<lpage>L7L8</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/ajplung.00196.2005</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X.-D.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Z. J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Sequence specific detection of bacterial 23S ribosomal RNA by TLR13</article-title>. <source>elife</source> <volume>1</volume>, <elocation-id>e00102</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.7554/eLife.00102.011</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>C.</given-names>
</name>
<name>
<surname>He</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Molecular characterisation of porcine miR-155 and its regulatory roles in the TLR3/TLR4 pathways</article-title>. <source>Dev. Comp. Immunol.</source> <volume>;39</volume>, <fpage>110</fpage>&#x2013;<lpage>116</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.dci.2012.01.001</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression <italic>via</italic> down-regulating checkpoint suppressor 1 in human lung cancer</article-title>. <source>PloS One</source> <volume>7</volume>, <elocation-id>e48278</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0048278</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Han</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>The therapeutic potential and clinical significance of exosomes as carriers of drug delivery system</article-title>. <source>Pharmaceutics</source> <volume>15</volume>, <fpage>21</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pharmaceutics15010021</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Pattern recognition receptors in health and diseases</article-title>. <source>Signal transduct. target. Ther.</source> <volume>6</volume>, <fpage>291</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41392-021-00687-0</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname> <given-names>W.-T.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>H.-H.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>C.-W.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y.-F.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Ho</surname> <given-names>J. H.-C.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>: Modulation of experimental acute lung injury by exosomal miR-7704 from mesenchymal stromal cells acts through M2 macrophage polarization and inflammation resolution</article-title>. <source>Mol. Therapy-Nucleic Acids</source> <volume>35</volume> (<issue>1</issue>), <fpage>102102</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.omtn.2023.102102</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The beneficial effects of mesenchymal stem cells in acute kidney injury: A narrative review</article-title>. <source>Curr. Stem Cell Res. Ther.</source> <volume>19</volume>, <fpage>200</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/1574888X18666230206115046</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Exosomal microRNA-342-5p secreted from adipose-derived mesenchymal stem cells mitigates acute kidney injury in sepsis mice by inhibiting TLR9</article-title>. <source>Biol. Proced. Online.</source> <volume>25</volume> (<issue>1</issue>), <fpage>10</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12575-023-00198-y</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>Z.-Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y.-J.</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Macrophage-derived exosomes promote bone mesenchymal stem cells towards osteoblastic fate through microRNA-21a-5p</article-title>. <source>Front. Bioeng. Biotechnol.</source> <volume>9</volume>, <elocation-id>801432</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fbioe.2021.801432</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X.-J.</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>J.-L.</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>H.-X.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>MiR-21 alleviates renal tubular epithelial cells injury induced by ischemia by targeting TLR4</article-title>. <source>Heliyon</source> <volume>9</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e15818</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loo</surname> <given-names>Y.-M.</given-names>
</name>
<name>
<surname>Gale</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Immune signaling by RIG-I-like receptors</article-title>. <source>Immunity</source> <volume>34</volume>, <fpage>680</fpage>&#x2013;<lpage>692</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.003</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lundberg</surname> <given-names>A. M.</given-names>
</name>
<name>
<surname>Ketelhuth</surname> <given-names>D. F.</given-names>
</name>
<name>
<surname>Johansson</surname> <given-names>M. E.</given-names>
</name>
<name>
<surname>Gerdes</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Yamamoto</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis</article-title>. <source>Cardiovasc. Res.</source> <volume>99</volume>, <fpage>364</fpage>&#x2013;<lpage>373</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/cvr/cvt033</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zhan</surname> <given-names>J.</given-names>
</name>
<name>
<surname>You</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>X.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>MicroRNA&#x2212;146a/Toll&#x2212;like receptor 4 signaling protects against severe burn&#x2212;induced remote acute lung injury in rats <italic>via</italic> anti&#x2212;inflammation</article-title>. <source>Mol. Med. Rep.</source> <volume>17</volume>, <fpage>8377</fpage>&#x2013;<lpage>8384</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/mmr</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manik</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>R. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19</article-title>. <source>J. Med. virol.</source> <volume>94</volume>, <fpage>869</fpage>&#x2013;<lpage>877</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmv.27405</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Q.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Roles and mechanisms of exosomal microRNAs in viral infections</article-title>. <source>Arch. Virol.</source> <volume>168</volume>, <fpage>121</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00705-023-05744-3</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Warrington</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Watson</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>H. L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>An introduction to immunology and immunopathology</article-title>. <source>Allergy Asthma Clin. Immunol.</source> <volume>14</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13223-018-0278-1</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Medzhitov</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Toll-like receptors and innate immunity</article-title>. <source>Nat. Rev. Immunol.</source> <volume>1</volume>, <fpage>135</fpage>&#x2013;<lpage>145</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/35100529</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendt</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Rezvani</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Shpall</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Mesenchymal stem cell-derived exosomes for clinical use</article-title>. <source>Bone marrow transplant.</source> <volume>54</volume>, <fpage>789</fpage>&#x2013;<lpage>792</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41409-019-0616-z</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merad</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Martin</surname> <given-names>J. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages</article-title>. <source>Nat. Rev. Immunol.</source> <volume>20</volume>, <fpage>355</fpage>&#x2013;<lpage>362</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-020-0331-4</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meydan</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Bekenstein</surname> <given-names>U.</given-names>
</name>
<name>
<surname>Soreq</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Molecular regulatory pathways link sepsis with metabolic syndrome: non-coding RNA elements underlying the sepsis/metabolic cross-talk</article-title>. <source>Front. Mol. Neurosci.</source> <volume>11</volume>, <elocation-id>189</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fnmol.2018.00189</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mielcarska</surname> <given-names>M. B.</given-names>
</name>
<name>
<surname>Bossowska-Nowicka</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Toka</surname> <given-names>F. N.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cell surface expression of endosomal Toll-like receptors&#x2014;A necessity or a superfluous duplication</article-title>? <source>Front. Immunol.</source> <volume>11</volume>, <elocation-id>620972</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.620972</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mobergslien</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Sioud</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Exosome-derived miRNAs and cellular miRNAs activate innate immunity</article-title>. <source>J. Innate Immun.</source> <volume>6</volume>, <fpage>105</fpage>&#x2013;<lpage>110</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000351460</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moghaddam</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Aghamollaei</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Kooshki</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Barjini</surname> <given-names>K. A.</given-names>
</name>
<name>
<surname>Mirnejad</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Choopani</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>The development of antimicrobial peptides as an approach to prevention of antibiotic resistance</article-title>. <source>Rev. Res. Med. Microbiol.</source> <volume>26</volume>, <fpage>98</fpage>&#x2013;<lpage>110</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MRM.0000000000000032</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Momen-Heravi</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Bala</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>miRNA regulation of innate immunity</article-title>. <source>J. leukocyte Biol.</source> <volume>103</volume>, <fpage>1205</fpage>&#x2013;<lpage>1217</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/JLB.3MIR1117-459R</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monlish</surname> <given-names>D. A.</given-names>
</name>
<name>
<surname>Bhatt</surname> <given-names>S. T.</given-names>
</name>
<name>
<surname>Schuettpelz</surname> <given-names>L. G.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The role of toll-like receptors in hematopoietic Malignancies</article-title>. <source>Front. Immunol.</source> <volume>7</volume>, <elocation-id>390</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2016.00390</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moosazadeh Moghaddam</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Fazel</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Fallah</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Sedighian</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Kachuei</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Behzadi</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Host and Pathogen-Directed Therapies against Microbial Infections Using Exosome-and Antimicrobial Peptide-derived Stem Cells with a Special look at Pulmonary Infections and Sepsis</article-title>. <source>Stem Cell Rev. Rep.</source> <volume>19</volume>, <fpage>2166</fpage>&#x2013;<lpage>2191</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12015-023-10594-2</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moravej</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Moravej</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Yazdanparast</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Heiat</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Mirhosseini</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Moosazadeh Moghaddam</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Antimicrobial peptides: features, action, and their resistance mechanisms in bacteria</article-title>. <source>Microbial. Drug Resist.</source> <volume>24</volume>, <fpage>747</fpage>&#x2013;<lpage>767</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/mdr.2017.0392</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukherjee</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Huda</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Sinha Babu</surname> <given-names>S. P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Toll-like receptor polymorphism in host immune response to infectious diseases: A review</article-title>. <source>Scandinavian J. Immunol.</source> <volume>90</volume>, <elocation-id>e12771</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/sji.12771</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nahid</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Satoh</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>E. K.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling</article-title>. <source>J. Immunol.</source> <volume>186</volume>, <fpage>1723</fpage>&#x2013;<lpage>1734</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1002311</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nation</surname> <given-names>G. K.</given-names>
</name>
<name>
<surname>Saffold</surname> <given-names>C. E.</given-names>
</name>
<name>
<surname>Pua</surname> <given-names>H. H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Secret messengers: Extracellular RNA communication in the immune system</article-title>. <source>Immunol. Rev.</source> <volume>304</volume>, <fpage>62</fpage>&#x2013;<lpage>76</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imr.13027</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nejad</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Stunden</surname> <given-names>H. J.</given-names>
</name>
<name>
<surname>Gantier</surname> <given-names>M. P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>A guide to miRNAs in inflammation and innate immune responses</article-title>. <source>FEBS J.</source> <volume>285</volume>, <fpage>3695</fpage>&#x2013;<lpage>3716</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/febs.14482</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nikfarjam</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Rezaie</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zolbanin</surname> <given-names>N. M.</given-names>
</name>
<name>
<surname>Jafari</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mesenchymal stem cell derived-exosomes: a modern approach in translational medicine</article-title>. <source>J. Trans. Med.</source> <volume>18</volume>, <fpage>1</fpage>&#x2013;<lpage>21</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12967-020-02622-3</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nik Mohamed Kamal</surname> <given-names>N. N. S. B.</given-names>
</name>
<name>
<surname>Shahidan</surname> <given-names>W. N. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Non-exosomal and exosomal circulatory microRNAs: which are more valid as biomarkers</article-title>? <source>Front. Pharmacol.</source> <volume>10</volume>, <elocation-id>1500</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2019.01500</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>N&#xfc;rnberger</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Kemmerling</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Pathogen-associated molecular patterns (PAMP) and PAMP-triggered immunity</article-title>. <source>Annu. Plant Rev.</source> <volume>34</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/9781119312994.apr0362</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Brien</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Hayder</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Zayed</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Overview of microRNA biogenesis, mechanisms of actions, and circulation</article-title>. <source>Front. endocrinol.</source> <volume>9</volume>, <elocation-id>402</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2018.00402</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira-Nascimento</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Massari</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Wetzler</surname> <given-names>L. M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The role of TLR2 in infection and immunity</article-title>. <source>Front. Immunol.</source> <volume>3</volume>, <elocation-id>79</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2012.00079</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ospelt</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Gay</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>TLRs and chronic inflammation</article-title>. <source>Int. J. Biochem. Cell Biol.</source> <volume>42</volume>, <fpage>495</fpage>&#x2013;<lpage>505</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biocel.2009.10.010</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandey</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Agrawal</surname> <given-names>D. K.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Immunobiology of Toll-like receptors: emerging trends</article-title>. <source>Immunol. Cell Biol.</source> <volume>84</volume>, <fpage>333</fpage>&#x2013;<lpage>341</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1440-1711.2006.01444.x</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandey</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Kawai</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Akira</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors</article-title>. <source>Cold Spring Harbor Perspect. Biol.</source> <volume>7</volume>, <fpage>a016246</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/cshperspect.a016246</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paul</surname> <given-names>S.</given-names>
</name>
<name>
<surname>V&#xe1;zquez</surname> <given-names>L. A. B.</given-names>
</name>
<name>
<surname>Reyes-P&#xe9;rez</surname> <given-names>P. R.</given-names>
</name>
<name>
<surname>Estrada-Meza</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Alburquerque</surname> <given-names>R. A. A.</given-names>
</name>
<name>
<surname>Pathak</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-review</article-title>. <source>Virus Res.</source> <volume>308</volume>, <fpage>198631</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.virusres.2021.198631</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pegtel</surname> <given-names>D. M.</given-names>
</name>
<name>
<surname>Gould</surname> <given-names>S. J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Exosomes</article-title>. <source>Annu. Rev. Biochem.</source> <volume>88</volume>, <fpage>487</fpage>&#x2013;<lpage>514</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-biochem-013118-111902</pub-id>
</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Per&#x161;e</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Ve&#x10d;eri&#x107;-Haler</surname> <given-names>&#x17d;.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Human umbilical cord blood mesenchymal stem cell transplantation in kidney injury animal models: A critical review</article-title>. <source>Stem Cells Reprod. Tissues Organs: From Fertil. to Cancer.</source>, <fpage>325</fpage>&#x2013;<lpage>348</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/etm.2020.9274</pub-id>
</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pevsner-Fischer</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Morad</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Cohen-Sfady</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Rousso-Noori</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Zanin-Zhorov</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Cohen</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2007</year>). <article-title>Toll-like receptors and their ligands control mesenchymal stem cell functions</article-title>. <source>Blood</source> <volume>109</volume>, <fpage>1422</fpage>&#x2013;<lpage>1432</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2006-06-028704</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfeiffer</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Ro&#xdf;manith</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Lang</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Falkenhagen</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an <italic>In vitro</italic> sepsis model</article-title>. <source>PloS One</source> <volume>12</volume>, <elocation-id>e0179850</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0179850</pub-id>
</citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piccinini</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Midwood</surname> <given-names>K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>DAMPening inflammation by modulating TLR signalling</article-title>. <source>Mediators inflamm.</source> <volume>2010</volume>:<fpage>672395</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2010/672395</pub-id>
</citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poli</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Fabi</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Bellet</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Costantini</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Nunziangeli</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Romani</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Epigenetic mechanisms of inflammasome regulation</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>, <fpage>5758</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms21165758</pub-id>
</citation>
</ref>
<ref id="B138">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poukkanen</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Wilkman</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Vaara</surname> <given-names>S. T.</given-names>
</name>
<name>
<surname>Pettil&#xe4;</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Kaukonen</surname> <given-names>K.-M.</given-names>
</name>
<name>
<surname>Korhonen</surname> <given-names>A.-M.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Hemodynamic variables and progression of acute kidney injury in critically ill patients with severe sepsis: data from the prospective observational FINNAKI study</article-title>. <source>Crit. Care</source> <volume>17</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/cc13161</pub-id>
</citation>
</ref>
<ref id="B139">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puente</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Alonso</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Lagan&#xe0;</surname> <given-names>A. S.</given-names>
</name>
<name>
<surname>Ghezzi</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Casarin</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Carugno</surname> <given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Chronic endometritis: old problem, novel insights and future challenges</article-title>. <source>Int. J. fertil steril.</source> <volume>13</volume>, <fpage>250</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.22074/IJFS.2020.5779</pub-id>
</citation>
</ref>
<ref id="B140">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pulendran</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Variegation of the immune response with dendritic cells and pathogen recognition receptors</article-title>. <source>J. Immunol.</source> <volume>174</volume>, <fpage>2457</fpage>&#x2013;<lpage>2465</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.174.5.2457</pub-id>
</citation>
</ref>
<ref id="B141">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qayum</surname> <given-names>A. A.</given-names>
</name>
<name>
<surname>Paranjape</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Abebayehu</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Kolawole</surname> <given-names>E. M.</given-names>
</name>
<name>
<surname>Haque</surname> <given-names>T. T.</given-names>
</name>
<name>
<surname>McLeod</surname> <given-names>J. J. A.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>IL-10&#x2013;induced miR-155 targets SOCS1 to enhance IgE-mediated mast cell function</article-title>. <source>J. Immunol.</source> <volume>196</volume>, <fpage>4457</fpage>&#x2013;<lpage>4467</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1502240</pub-id>
</citation>
</ref>
<ref id="B142">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname> <given-names>X.</given-names>
</name>
<name>
<surname>An</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Immunosuppressive effects of mesenchymal stem cells-derived exosomes</article-title>. <source>Stem Cell Rev. Rep.</source> <volume>17</volume>, <fpage>411</fpage>&#x2013;<lpage>427</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12015-020-10040-7</pub-id>
</citation>
</ref>
<ref id="B143">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Toxoplasma gondii microneme protein MIC3 induces macrophage TNF-&#x3b1; production and Ly6C expression <italic>via</italic> TLR11/MyD88 pathway</article-title>. <source>PloS Negl. Trop. Dis.</source> <volume>17</volume>, <elocation-id>e0011105</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0011105</pub-id>
</citation>
</ref>
<ref id="B144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramesh</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Reeves</surname> <given-names>W. B.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Inflammatory cytokines in acute renal failure</article-title>. <source>Kidney Int.</source> <volume>66</volume>, <fpage>S56</fpage>&#x2013;<lpage>S61</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.09109.x</pub-id>
</citation>
</ref>
<ref id="B145">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Relja</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Land</surname> <given-names>W. G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Damage-associated molecular patterns in trauma</article-title>. <source>Eur. J. Trauma Emergency surge.</source> <volume>46</volume>, <fpage>751</fpage>&#x2013;<lpage>775</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00068-019-01235-w</pub-id>
</citation>
</ref>
<ref id="B146">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhee</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Kadri</surname> <given-names>S. S.</given-names>
</name>
<name>
<surname>Dekker</surname> <given-names>J. P.</given-names>
</name>
<name>
<surname>Danner</surname> <given-names>R. L.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H.-C.</given-names>
</name>
<name>
<surname>Fram</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use</article-title>. <source>JAMA Netw. Open</source> <volume>3</volume>, <fpage>e202899</fpage>&#x2013;<lpage>e</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.2899</pub-id>
</citation>
</ref>
<ref id="B147">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riera Romo</surname> <given-names>M.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Mart&#xed;nez</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Castillo Ferrer</surname> <given-names>C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Innate immunity in vertebrates: an overview</article-title>. <source>Immunology</source> <volume>148</volume>, <fpage>125</fpage>&#x2013;<lpage>139</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imm.12597</pub-id>
</citation>
</ref>
<ref id="B148">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roh</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Sohn</surname> <given-names>D. H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Damage-associated molecular patterns in inflammatory diseases</article-title>. <source>Immune netw.</source> <volume>18</volume> (<issue>4</issue>), <elocation-id>e27</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.4110/in.2018.18.e27</pub-id>
</citation>
</ref>
<ref id="B149">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruytinx</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Proost</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Van Damme</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Struyf</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Chemokine-induced macrophage polarization in inflammatory conditions</article-title>. <source>Front. Immunol.</source> <volume>9</volume>, <elocation-id>1930</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.01930</pub-id>
</citation>
</ref>
<ref id="B150">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saikh</surname> <given-names>K. U.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>MyD88 and beyond: A perspective on MyD88-targeted therapeutic approach for modulation of host immunity</article-title>. <source>Immunol. Res.</source> <volume>69</volume>, <fpage>117</fpage>&#x2013;<lpage>128</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12026-021-09188-2</pub-id>
</citation>
</ref>
<ref id="B151">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sallustio</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Curci</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Stasi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>De Palma</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Divella</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Gramignoli</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Role of toll-like receptors in actuating stem/progenitor cell repair mechanisms: different functions in different cells</article-title>. <source>Stem Cells Int.</source> <volume>2019</volume>, <fpage>6795845</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/6795845</pub-id>
</citation>
</ref>
<ref id="B152">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sameer</surname> <given-names>A. S.</given-names>
</name>
<name>
<surname>Nissar</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Toll-like receptors (TLRs): structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility</article-title>. <source>BioMed. Res. Int.</source> <volume>2021</volume>, <fpage>1157023</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2021/1157023</pub-id>
</citation>
</ref>
<ref id="B153">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampey</surname> <given-names>G. C.</given-names>
</name>
<name>
<surname>Saifuddin</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Schwab</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Barclay</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Punya</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>M.-C.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Exosomes from HIV-1-infected cells stimulate production of pro-inflammatory cytokines through trans-activating response (TAR) RNA</article-title>. <source>J. Biol. Chem.</source> <volume>291</volume>, <fpage>1251</fpage>&#x2013;<lpage>1266</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M115.662171</pub-id>
</citation>
</ref>
<ref id="B154">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>S&#xe1;vio-Silva</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Soinski-Sousa</surname> <given-names>P. E.</given-names>
</name>
<name>
<surname>Balby-Rocha</surname> <given-names>M. T. A.</given-names>
</name>
<name>
<surname>&#xc1;dO</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Rangel</surname> <given-names>&#xc9;B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mesenchymal stem cell therapy in acute kidney injury (AKI): review and perspectives</article-title>. <source>Rev. da Associa&#xe7;&#xe3;o M&#xe9;dica Brasileira.</source> <volume>66</volume>, <fpage>s45</fpage>&#x2013;<lpage>s54</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/1806-9282.66.s1.45</pub-id>
</citation>
</ref>
<ref id="B155">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savva</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Roger</surname> <given-names>T.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases</article-title>. <source>Front. Immunol.</source> <volume>4</volume>, <elocation-id>387</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2013.00387</pub-id>
</citation>
</ref>
<ref id="B156">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schinkel</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Panday</surname> <given-names>R. S. N.</given-names>
</name>
<name>
<surname>Wiersinga</surname> <given-names>W. J.</given-names>
</name>
<name>
<surname>Nanayakkara</surname> <given-names>P. W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Timeliness of antibiotics for patients with sepsis and septic shock</article-title>. <source>J. Thorac. dis.</source> <volume>12</volume>, <fpage>S66</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/jtd</pub-id>
</citation>
</ref>
<ref id="B157">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Oberle</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Krammer</surname> <given-names>P. H.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Molecular mechanisms of treg-mediated T cell suppression</article-title>. <source>Front. Immunol.</source> <volume>3</volume>, <elocation-id>51</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2012.00051</pub-id>
</citation>
</ref>
<ref id="B158">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schultz</surname> <given-names>I. C.</given-names>
</name>
<name>
<surname>Bertoni</surname> <given-names>A. P. S.</given-names>
</name>
<name>
<surname>Wink</surname> <given-names>M. R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mesenchymal stem cell-derived extracellular vesicles carrying miRNA as a potential multi target therapy to COVID-19: an in silico analysis</article-title>. <source>Stem Cell Rev. Rep.</source> <volume>17</volume>, <fpage>341</fpage>&#x2013;<lpage>356</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12015-021-10122-0</pub-id>
</citation>
</ref>
<ref id="B159">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Self-Fordham</surname> <given-names>J. B.</given-names>
</name>
<name>
<surname>Naqvi</surname> <given-names>A. R.</given-names>
</name>
<name>
<surname>Uttamani</surname> <given-names>J. R.</given-names>
</name>
<name>
<surname>Kulkarni</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Nares</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>MicroRNA: dynamic regulators of macrophage polarization and plasticity</article-title>. <source>Front. Immunol.</source> <volume>8</volume>, <elocation-id>1062</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2017.01062</pub-id>
</citation>
</ref>
<ref id="B160">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapouri-Moghaddam</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Mohammadian</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Vazini</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Taghadosi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Esmaeili</surname> <given-names>S. A.</given-names>
</name>
<name>
<surname>Mardani</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Macrophage plasticity, polarization, and function in health and disease</article-title>. <source>J. Cell. Physiol.</source> <volume>233</volume>, <fpage>6425</fpage>&#x2013;<lpage>6440</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jcp.26429</pub-id>
</citation>
</ref>
<ref id="B161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shekarian</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Valsesia-Wittmann</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Brody</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Michallet</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Depil</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Caux</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Pattern recognition receptors: immune targets to enhance cancer immunotherapy</article-title>. <source>Ann. Oncol.</source> <volume>28</volume>, <fpage>1756</fpage>&#x2013;<lpage>1766</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/annonc/mdx179</pub-id>
</citation>
</ref>
<ref id="B162">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shim</surname> <given-names>J.-H.</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Paschal</surname> <given-names>A. E.</given-names>
</name>
<name>
<surname>Bailey</surname> <given-names>S. T.</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Hayden</surname> <given-names>M. S.</given-names>
</name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo</article-title>. <source>Genes Dev.</source> <volume>19</volume>, <fpage>2668</fpage>&#x2013;<lpage>2681</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/gad.1360605</pub-id>
</citation>
</ref>
<ref id="B163">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shirjang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Mansoori</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Solali</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Hagh</surname> <given-names>M. F.</given-names>
</name>
<name>
<surname>Shamsasenjan</surname> <given-names>K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Toll-like receptors as a key regulator of mesenchymal stem cell function: an up-to-date review</article-title>. <source>Cell. Immunol.</source> <volume>315</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cellimm.2016.12.005</pub-id>
</citation>
</ref>
<ref id="B164">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shomali</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Mahmoodpoor</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Abbas Abad</surname> <given-names>A. N.</given-names>
</name>
<name>
<surname>Marofi</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Akbari</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>The relationship between extracellular/intracellular microRNAs and TLRs may be used as a diagnostic and therapeutic approach in sepsis</article-title>. <source>Immunol. Investig.</source> <volume>51</volume>, <fpage>154</fpage>&#x2013;<lpage>169</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/08820139.2020.1817067</pub-id>
</citation>
</ref>
<ref id="B165">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sol&#xe0;</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Gluud</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Lathyris</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Anand</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Mart&#xed;Carvajal</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients</article-title>. <source>Cochrane Database system. Rev.</source> <volume>2012</volume> (<issue>12</issue>), <fpage>CD004388</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/14651858.CD004388.pub6</pub-id>
</citation>
</ref>
<ref id="B166">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Dou</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1&#x3b2;-primed mesenchymal stem cells against sepsis</article-title>. <source>Stem Cells</source> <volume>35</volume>, <fpage>1208</fpage>&#x2013;<lpage>1221</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/stem.2564</pub-id>
</citation>
</ref>
<ref id="B167">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stejskalova</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Janova</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Splichalova</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Futas</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Oppelt</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Vodicka</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2024</year>). <article-title>Twelve toll-like receptor (TLR) genes in the family Equidae&#x2013;comparative genomics, selection and evolution</article-title>. <source>Vet. Res. Commun.</source> <volume>48</volume>, <fpage>725</fpage>&#x2013;<lpage>741</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11259-023-10245-4</pub-id>
</citation>
</ref>
<ref id="B168">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suresh</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Mosser</surname> <given-names>D. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Pattern recognition receptors in innate immunity, host defense, and immunopathology</article-title>. <source>Adv. Physiol. educ.</source> <volume>37</volume>, <fpage>284</fpage>&#x2013;<lpage>291</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/advan.00058.2013</pub-id>
</citation>
</ref>
<ref id="B169">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szil&#xe1;gyi</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Fejes</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>P&#xf3;csi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Kappelmayer</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Nagy</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Role of sepsis modulated circulating microRNAs</article-title>. <source>Ejifcc</source> <volume>30</volume>, <fpage>128</fpage>.</citation>
</ref>
<ref id="B170">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeuchi</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Hoshino</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Akira</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection</article-title>. <source>J. Immunol.</source> <volume>165</volume>, <fpage>5392</fpage>&#x2013;<lpage>5396</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.165.10.5392</pub-id>
</citation>
</ref>
<ref id="B171">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>K. W. K.</given-names>
</name>
<name>
<surname>Millar</surname> <given-names>B. C.</given-names>
</name>
<name>
<surname>Moore</surname> <given-names>J. E.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Antimicrobial resistance (AMR)</article-title>. <source>Br. J. Biomed. Sci.</source> <volume>80</volume>, <fpage>11387</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/bjbs.2023.11387</pub-id>
</citation>
</ref>
<ref id="B172">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Toll-like receptors and thrombopoiesis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>24</volume>, <fpage>1010</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms24021010</pub-id>
</citation>
</ref>
<ref id="B173">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teo</surname> <given-names>K. Y. W.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Loh</surname> <given-names>J. T.</given-names>
</name>
<name>
<surname>Lai</surname> <given-names>R. C.</given-names>
</name>
<name>
<surname>Hey</surname> <given-names>H. W. D.</given-names>
</name>
<name>
<surname>Lam</surname> <given-names>K.-P.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Mesenchymal stromal cell exosomes mediate M2-like macrophage polarization through CD73/ecto-5&#x2032;-nucleotidase activity</article-title>. <source>Pharmaceutics</source> <volume>15</volume>, <fpage>1489</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pharmaceutics15051489</pub-id>
</citation>
</ref>
<ref id="B174">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ti</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Hao</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation <italic>via</italic> exosome-shuttled let-7b</article-title>. <source>J. Trans. Med.</source> <volume>13</volume>, <fpage>1</fpage>&#x2013;<lpage>14</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12967-015-0642-6</pub-id>
</citation>
</ref>
<ref id="B175">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tugal</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Jain</surname> <given-names>M. K.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Transcriptional control of macrophage polarization</article-title>. <source>Arteriosclerosis thromb. Vasc. Biol.</source> <volume>33</volume>, <fpage>1135</fpage>&#x2013;<lpage>1144</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/ATVBAHA.113.301453</pub-id>
</citation>
</ref>
<ref id="B176">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ullah</surname> <given-names>M. O.</given-names>
</name>
<name>
<surname>Sweet</surname> <given-names>M. J.</given-names>
</name>
<name>
<surname>Mansell</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Kellie</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Kobe</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target</article-title>. <source>J. Leucocyte Biol.</source> <volume>100</volume>, <fpage>27</fpage>&#x2013;<lpage>45</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1189/jlb.2RI1115-531R</pub-id>
</citation>
</ref>
<ref id="B177">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varma</surname> <given-names>D. M.</given-names>
</name>
<name>
<surname>Zahid</surname> <given-names>M. S. H.</given-names>
</name>
<name>
<surname>Bachelder</surname> <given-names>E. M.</given-names>
</name>
<name>
<surname>Ainslie</surname> <given-names>K. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Formulation of host-targeted therapeutics against bacterial infections</article-title>. <source>Trans. Res.</source> <volume>220</volume>, <fpage>98</fpage>&#x2013;<lpage>113</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.trsl.2020.03.009</pub-id>
</citation>
</ref>
<ref id="B178">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasilescu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Rossi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Shimizu</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Tudor</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Veronese</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Ferracin</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis</article-title>. <source>PloS One</source> <volume>4</volume>, <elocation-id>e7405</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0007405</pub-id>
</citation>
</ref>
<ref id="B179">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>V&#xe1;zquez-Carballo</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Guerrero-Hue</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Caballero</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Rayego-Mateos</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Opazo-R&#xed;os</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Morgado-Pascual</surname> <given-names>J. L.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Toll-like receptors in acute kidney injury</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>, <fpage>816</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms22020816</pub-id>
</citation>
</ref>
<ref id="B180">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vijay</surname> <given-names>K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Toll-like receptors in immunity and inflammatory diseases: Past, present, and future</article-title>. <source>Int. immunopharmacol.</source> <volume>59</volume>, <fpage>391</fpage>&#x2013;<lpage>412</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2018.03.002</pub-id>
</citation>
</ref>
<ref id="B181">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallis</surname> <given-names>R. S.</given-names>
</name>
<name>
<surname>O&#x2019;Garra</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Sher</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Wack</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Host-directed immunotherapy of viral and bacterial infections: past, present and future</article-title>. <source>Nat. Rev. Immunol.</source> <volume>23</volume>, <fpage>121</fpage>&#x2013;<lpage>133</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-022-00734-z</pub-id>
</citation>
</ref>
<ref id="B182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Essandoh</surname> <given-names>K.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Exosomal miR-223 contributes to mesenchymal stem cell-elicited cardioprotection in polymicrobial sepsis</article-title>. <source>Sci. Rep.</source> <volume>5</volume>, <fpage>13721</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep13721</pub-id>
</citation>
</ref>
<ref id="B183">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>W. W.</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Negative regulation of Toll-like receptor signaling pathway</article-title>. <source>Microbes infect.</source> <volume>11</volume>, <fpage>321</fpage>&#x2013;<lpage>327</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.micinf.2008.12.011</pub-id>
</citation>
</ref>
<ref id="B184">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Exosomes from adipose-derived stem cells suppress the progression of chronic endometritis</article-title>. <source>Cell Transplant.</source> <volume>32</volume>, <fpage>09636897231173736</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/09636897231173736</pub-id>
</citation>
</ref>
<ref id="B185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Zen</surname> <given-names>K.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Molecular mechanisms that influence the macrophage M1&#x2013;M2 polarization balance</article-title>. <source>Front. Immunol.</source> <volume>5</volume>, <elocation-id>614</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2014.00614</pub-id>
</citation>
</ref>
<ref id="B186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Lou</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Du</surname> <given-names>Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>LncRNA SNHG16 reverses the effects of miR-15a/16 on LPS-induced inflammatory pathway</article-title>. <source>Biomed. Pharmacother.</source> <volume>106</volume>, <fpage>1661</fpage>&#x2013;<lpage>1667</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2018.07.105</pub-id>
</citation>
</ref>
<ref id="B187">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Shu</surname> <given-names>Q.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Mesenchymal stem cell-derived extracellular vesicles alter disease outcomes <italic>via</italic> endorsement of macrophage polarization</article-title>. <source>Stem Cell Res. Ther.</source> <volume>11</volume>, <fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13287-020-01937-8</pub-id>
</citation>
</ref>
<ref id="B188">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warrington</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Watson</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>H. L.</given-names>
</name>
<name>
<surname>Antonetti</surname> <given-names>F. R.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>An introduction to immunology and immunopathology</article-title>. <source>Allergy Asthma Clin. Immunol.</source> <volume>7</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1710-1492-7-S1-S1</pub-id>
</citation>
</ref>
<ref id="B189">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waterman</surname> <given-names>R. S.</given-names>
</name>
<name>
<surname>Tomchuck</surname> <given-names>S. L.</given-names>
</name>
<name>
<surname>Henkle</surname> <given-names>S. L.</given-names>
</name>
<name>
<surname>Betancourt</surname> <given-names>A. M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype</article-title>. <source>PloS One</source> <volume>5</volume>, <elocation-id>e10088</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0010088</pub-id>
</citation>
</ref>
<ref id="B190">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>MyD88 as a target of microRNA-203 in regulation of lipopolysaccharide or Bacille Calmette-Guerin induced inflammatory response of macrophage RAW264. 7 cells</article-title>. <source>Mol. Immunol.</source> <volume>55</volume>, <fpage>303</fpage>&#x2013;<lpage>309</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2013.03.004</pub-id>
</citation>
</ref>
<ref id="B191">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Sui</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>MicroRNA-377-3p released by mesenchymal stem cell exosomes ameliorates lipopolysaccharide-induced acute lung injury by targeting RPTOR to induce autophagy</article-title>. <source>Cell Death Dis.</source> <volume>11</volume>, <fpage>657</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41419-020-02857-4</pub-id>
</citation>
</ref>
<ref id="B192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wendlandt</surname> <given-names>E. B.</given-names>
</name>
<name>
<surname>Graff</surname> <given-names>J. W.</given-names>
</name>
<name>
<surname>Gioannini</surname> <given-names>T. L.</given-names>
</name>
<name>
<surname>McCaffrey</surname> <given-names>A. P.</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>M. E.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The role of microRNAs miR-200b and miR-200c in TLR4 signaling and NF-&#x3ba;B activation</article-title>. <source>Innate immun.</source> <volume>18</volume>, <fpage>846</fpage>&#x2013;<lpage>855</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/1753425912443903</pub-id>
</citation>
</ref>
<ref id="B193">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wicherska-Paw&#x142;owska</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Wr&#xf3;bel</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Rybka</surname> <given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>, <fpage>13397</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms222413397</pub-id>
</citation>
</ref>
<ref id="B194">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Lian</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>Q.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Research progress on Toll-like receptor signal transduction and its roles in antimicrobial immune responses</article-title>. <source>Appl. Microbiol. Biotechnol.</source> <volume>105</volume>, <fpage>5341</fpage>&#x2013;<lpage>5355</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00253-021-11406-8</pub-id>
</citation>
</ref>
<ref id="B195">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiu</surname> <given-names>G.-h.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.-l.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X.-z.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>B.-q.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X.-l.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Role of bone marrow mesenchymal stromal cells in attenuating inflammatory reaction in lipopolysaccaride-induced acute kidney injury of rats associated with TLR4-NF-&#x3ba;B signaling pathway inhibition</article-title>. <source>Ann. Clin. Lab. Sci.</source> <volume>48</volume>, <fpage>743</fpage>&#x2013;<lpage>750</lpage>.</citation>
</ref>
<ref id="B196">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Jeyaram</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Jay</surname> <given-names>S. M.</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Chao</surname> <given-names>W.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Circulating plasma extracellular vesicles from septic mice induce inflammation <italic>via</italic> microRNA-and TLR7-dependent mechanisms</article-title>. <source>J. Immunol.</source> <volume>201</volume>, <fpage>3392</fpage>&#x2013;<lpage>3400</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1801008</pub-id>
</citation>
</ref>
<ref id="B197">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Xing</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Ge</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Microrna-149 negatively regulates tlr-triggered inflammatory response in macrophages by targeting myd88</article-title>. <source>J. Cell. Biochem.</source> <volume>115</volume>, <fpage>919</fpage>&#x2013;<lpage>927</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jcb.24734</pub-id>
</citation>
</ref>
<ref id="B198">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yagi</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Soto-Gutierrez</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Parekkadan</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Kitagawa</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Tompkins</surname> <given-names>R. G.</given-names>
</name>
<name>
<surname>Kobayashi</surname> <given-names>N.</given-names>
</name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>Mesenchymal stem cells: mechanisms of immunomodulation and homing</article-title>. <source>Cell transplant.</source> <volume>19</volume>, <fpage>667</fpage>&#x2013;<lpage>679</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3727/096368910X508762</pub-id>
</citation>
</ref>
<ref id="B199">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Hemmi</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Hoshino</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Kaisho</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Sanjo</surname> <given-names>H.</given-names>
</name>
<etal/>
</person-group>. (<year>2003</year>). <article-title>Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway</article-title>. <source>Science</source> <volume>301</volume>, <fpage>640</fpage>&#x2013;<lpage>643</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1087262</pub-id>
</citation>
</ref>
<ref id="B200">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Exosomes as potential functional nanomaterials for tissue engineering</article-title>. <source>Adv. healthc. mater.</source> <volume>12</volume>, <fpage>2201989</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/adhm.202201989</pub-id>
</citation>
</ref>
<ref id="B201">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>H.</given-names>
</name>
<name>
<surname>An</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Exosomes derived from microRNA-30b-3p-overexpressing mesenchymal stem cells protect against lipopolysaccharide-induced acute lung injury by inhibiting SAA3</article-title>. <source>Exp. Cell Res.</source> <volume>383</volume>, <fpage>111454</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yexcr.2019.05.035</pub-id>
</citation>
</ref>
<ref id="B202">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanoni</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Ostuni</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Marek</surname> <given-names>L. R.</given-names>
</name>
<name>
<surname>Barresi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Barbalat</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Barton</surname> <given-names>G. M.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>CD14 controls the LPS-induced endocytosis of Toll-like receptor 4</article-title>. <source>Cell</source> <volume>147</volume>, <fpage>868</fpage>&#x2013;<lpage>880</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2011.09.051</pub-id>
</citation>
</ref>
<ref id="B203">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Bu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Downregulated expression of miR-223 promotes Toll-like receptor-activated inflammatory responses in macrophages by targeting RhoB</article-title>. <source>Mol. Immunol.</source> <volume>91</volume>, <fpage>42</fpage>&#x2013;<lpage>48</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2017.08.026</pub-id>
</citation>
</ref>
<ref id="B204">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Ghosh</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Toll-like receptor&#x2013;mediated NF-&#x3ba;B activation: a phylogenetically conserved paradigm in innate immunity</article-title>. <source>J. Clin. Invest.</source> <volume>107</volume>, <fpage>13</fpage>&#x2013;<lpage>19</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI11837</pub-id>
</citation>
</ref>
<ref id="B205">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Kraft</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Broering</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Schlaak</surname> <given-names>J. F.</given-names>
</name>
<name>
<surname>Dittmer</surname> <given-names>U.</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections</article-title>. <source>Expert Opin. Drug discov.</source> <volume>7</volume>, <fpage>597</fpage>&#x2013;<lpage>611</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1517/17460441.2012.689281</pub-id>
</citation>
</ref>
<ref id="B206">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Exosome and exosomal microRNA: trafficking, sorting, and function</article-title>. <source>Genom. Proteomics Bioinf.</source> <volume>13</volume>, <fpage>17</fpage>&#x2013;<lpage>24</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.gpb.2015.02.001</pub-id>
</citation>
</ref>
<ref id="B207">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>W. H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Exosomes: biogenesis, biologic function and clinical potential</article-title>. <source>Cell biosci.</source> <volume>9</volume>, <fpage>1</fpage>&#x2013;<lpage>18</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13578-019-0282-2</pub-id>
</citation>
</ref>
<ref id="B208">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Z.-J.</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.-Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>MicroRNA-574-5p directly targets FOXN3 to mediate thyroid cancer progression <italic>via</italic> Wnt/&#x3b2;-catenin signaling pathway</article-title>. <source>Pathology-Res. Pract.</source> <volume>216</volume>, <fpage>152939</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.prp.2020.152939</pub-id>
</citation>
</ref>
<ref id="B209">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Exosomes from adipose-derived stem cells inhibit inflammation and oxidative stress in LPS-acute kidney injury</article-title>. <source>Exp. Cell Res.</source> <volume>420</volume>, <fpage>113332</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yexcr.2022.113332</pub-id>
</citation>
</ref>
<ref id="B210">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Human umbilical cord mesenchymal stem cell exosomes alleviate sepsis-associated acute kidney injury <italic>via</italic> regulating microRNA-146b expression</article-title>. <source>Biotechnol. lett.</source> <volume>42</volume>, <fpage>669</fpage>&#x2013;<lpage>679</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10529-020-02831-2</pub-id>
</citation>
</ref>
<ref id="B211">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Cong</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>X.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Autophagy in sepsis-induced acute lung injury: Friend or foe</article-title>? <source>Cell. Signal.</source> <volume>111</volume>, <fpage>110867</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cellsig.2023.110867</pub-id>
</citation>
</ref>
<ref id="B212">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>The toll-like receptor 3 ligand, poly (I: C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis <italic>via</italic> inhibiting MiR-143</article-title>. <source>Stem Cells</source> <volume>32</volume>, <fpage>521</fpage>&#x2013;<lpage>533</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/stem.1543</pub-id>
</citation>
</ref>
<ref id="B213">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Biogenesis and function of extracellular miRNAs</article-title>. <source>ExRNA</source> <volume>1</volume>, <fpage>1</fpage>&#x2013;<lpage>9</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s41544-019-0039-4</pub-id>
</citation>
</ref>
<ref id="B214">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Liwinski</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Elinav</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Interaction between microbiota and immunity in health and disease</article-title>. <source>Cell Res.</source> <volume>30</volume>, <fpage>492</fpage>&#x2013;<lpage>506</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41422-020-0332-7</pub-id>
</citation>
</ref>
<ref id="B215">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zindel</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Kubes</surname> <given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation</article-title>. <source>Annu. Rev. Pathol.: Mech. Dis.</source> <volume>15</volume>, <fpage>493</fpage>&#x2013;<lpage>518</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-012419-032847</pub-id>
</citation>
</ref>
<ref id="B216">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zingale</surname> <given-names>V. D.</given-names>
</name>
<name>
<surname>Gugliandolo</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Mazzon</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>MiR-155: an important regulator of Neuroinflammation</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>, <fpage>90</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms23010090</pub-id>
</citation>
</ref>
<ref id="B217">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zumla</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Wallis</surname> <given-names>R. S.</given-names>
</name>
<name>
<surname>Kaufmann</surname> <given-names>S. H.</given-names>
</name>
<name>
<surname>Rustomjee</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Mwaba</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Host-directed therapies for infectious diseases: current status, recent progress, and future prospects</article-title>. <source>Lancet Infect. Dis.</source> <volume>16</volume>, <fpage>e47</fpage>&#x2013;<lpage>e63</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1473-3099(16)00078-5</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>